UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ ~~QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934~~	QUARTERLY REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

	For the three and nine months ended: February 28, 2022

	OR

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

	For the transition period from _______________ to _______________

~~For the quarterly period ended~~Commission file number: ~~August 31, 2021~~333-216292

~~Commission File Number 333-216292~~

INSTADOSE PHARMA CORP.

~~(Exact~~ (Exact name of ~~registrant as specified~~Company in its charter)

Nevada		81-3599639
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer ~~Identification No.)~~Identification)

~~1545 Crossways Blvd.,~~5500 North Service Road, Suite ~~250, Chesapeake, Virginia, 23320-0210~~301

Burlington, Ontario, L7L 6W6

(Address of principal executive ~~offices)(Zip Code)~~offices, including zip code)

~~(800) 701-4342~~

(Registrant’s ~~telephone~~Telephone number, including area ~~code)~~code: (800) 701-4342

~~MIKROCOZE, INC.~~Securities registered pursuant to Section 12(b) of the Act: None

~~(Former name, former address and former fiscal year,~~

Securities registered pursuant to Section 12(g) of the Act: Common Stock, $0.001 par value

Indicate by check mark if ~~changed since last report)~~the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Exchange Act. Yes ☐ No ☒

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (section 232.406 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act ~~of 1934~~ during the preceding 12 months (or ~~for~~ such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for at least the ~~past~~part 90 days. Yes

☒ ~~Yes~~No ☐ No

Indicate by check mark ~~whether the registrant has submitted electronically,~~ if ~~any, every Interactive Data File required~~disclosure of delinquent filers in response to ~~be submitted pursuant to Rule~~Item 405 of Regulation ~~S-T (§232.405~~S-K is not contained hereof, and will not be contained, to will be contained, to the best of the registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this ~~chapter) during the preceding 12 months (or for such shorter period that the registrant was required~~Form 10-K or any amendment to ~~submit such files).~~this Form 10-K. ☐ ~~Yes ☒ No~~

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. ~~See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.~~

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated ~~filer~~Filer	☒	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☒ Yes ☐ No ☒

~~APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY PROCEEDINGS DURING THE PRECEDING FIVE YEARS:~~State the aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant’s most recently completed second fiscal quarter. The market value of the registrant’s voting $0.0001 par value common stock held by non-affiliates of the registrant at July 31, 2021, was approximately $125,000.

Indicate ~~by check mark whether~~ the ~~registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d)~~number of shares outstanding of each of the ~~Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court ☐ Yes ☐ No~~

~~Securities registered pursuant to Section 12(b) of the Act:~~

~~Title of each class~~

~~Trading Symbol(s)~~

~~Name of each exchange on which registered~~

~~Common, $0.0001 Par Value~~

~~INSD~~

~~OTCBB~~

~~As of October 13, 2021 the registrant had 75,001,200 shares~~registrant’s classes of common stock, ~~issued and 75,001,200~~as of the latest practicable date. The number of shares outstanding of the registrant’s only class of common stock, ~~outstanding,~~as of May 9, 2022, was 531,933,749 shares of its $0.0001 par value ~~$0.0001.~~common stock.

No documents are incorporated into the text by reference.

Instadose Pharma Corp.

Form 10-Q

For the Three and Nine Months Ended February 28, 2022

~~TABLE~~Table of ~~CONTENTS~~Contents

			~~PART I—FINANCIAL INFORMATION~~Page
Part I
Item 1	Condensed Financial Statements		3
Item 2	Management’s Discussion and Analysis of Financial Conditions and Results		33
Item 3	Quantitative and Qualitative Disclosures About Market Risk		36
Item 4	Controls and Procedures		36

~~Item 1.~~Part II				~~Condensed Financial Statements.~~	3
~~Item 2.~~	~~Management’s Discussion and Analysis of Financial Condition and Results of Operations.~~	13
~~Item 3.~~	~~Quantitative and Qualitative Disclosures About Market Risk.~~	15
~~Item 4.~~	~~Controls and Procedures.~~	15

~~PART II—OTHER INFORMATION~~		16

Item 1.	Legal ~~Proceedings.~~Proceedings	16	37
Item 1A.	Risk ~~Factors.~~Factors	16	37
Item 2.2	Unregistered Sales of Securities and Use of ~~Proceeds.~~Proceeds	16	44
Item 3.	Defaults Upon Senior ~~Securities.~~Securities	16	44
Item 4.	Mine Safety Disclosures	16	44
Item 5.	Other Information	16	45

Part III
Item 6.15.	~~Exhibits.~~Exhibits, Financial Statement Schedules	17	46
Signatures			47

PART I

ITEM 1. Condensed Financial Statements

Instadose Pharma Corp. and Subsidiaries

		Page(s)

Consolidated Balance Sheets		4

Consolidated Statements of Operations		5

Consolidated Statements of Changes in Stockholders’ Equity (Deficit)		6

Consolidated Statements of Cash Flows		7

Notes to Consolidated Financial Statements		8

Table of Contents

INSTADOSE PHARMA CORP

~~PART I—FINANCIAL INFORMATION~~BLANCE SHEETS

~~Item 1. Condensed Financial Statements.~~

	February 28, 2022			May 31, 2021
	(Unaudited)			(Audited)

Assets

Current Assets
Cash and cash equivalents	$	5,328		$	34,608
Prepaid and other current assets		83,847			98,753
Total Current Assets		89,175			133,361

Due from related party		1,732,652			929,463

Joint ventures		93,371			29,881

Property, plant and equipment - net		3,833,741			3,223,598

Operating lease - right-of-use asset		169,805			242,579

Intangible rights		40,021,182			41,395,950

Total Assets	$	45,939,926		$	45,954,832

Liabilities and Stockholders' Deficit

Current Liabilities
Accounts payable and accrued expenses	$	5,005,022		$	2,297,378
Accrued compensation - related parties		4,239,433			3,137,350
Common stock payable (400,000 shares)		800,000			800,000
Loan payable - related party		51,831			39,693,970
Operating lease liability		103,688			101,642
Total Current Liabilities		10,199,974			46,030,340

Operating lease liability		82,005			168,499

Total Liabilities		10,281,979			46,198,839

Commitments and Contingencies (Note 7)

Retained Earnings/Stockholders' Deficit
Common stock, no par value, unlimited shares authorized 531,933,749 and 510,553,509 shares issued and outstanding, respectively		178,645,296			135,884,807
Additional paid-in capital		29,736,666			(1,215,473	)
Accumulated deficit		(172,724,015	)		(134,913,341	)
Total Retained Earnings/Stockholders' Deficit		35,657,947			(244,007	)

Total Liabilities and Stockholders' Deficit	$	45,939,926		$	45,954,832

~~INSTADOSE PHARMA CORP.~~

~~(formerly Mikrocoze Inc.)~~

~~FINANCIAL STATEMENTS~~

~~August 31, 2021~~The accompanying notes are an integral part of these financial statements.

~~CONDENSED BALANCE SHEETS~~
4
4

*~~CONDENSED STATEMENTS OF OPERATIONS~~Table of Contents*	5

~~CONDENSED STATEMENT OF STOCKHOLDERS’ DEFICIT~~	6

~~CONDENSED STATEMENTS OF CASH FLOWS~~	7

~~CONDENSED NOTES TO FINANCIAL STATEMENTS~~	8

INSTADOSE PHARMA CORP

STATEMENT OF OPERATIONS

	Three Months Ended						Nine Months Ended
	February 28						February 28
	2022			2021			2022			2021

General and administrative expenses		666,714			12,852,422			36,395,938			19,266,106

Loss from operations		(666,714	)		(12,852,422	)		(36,395,938	)		(19,266,106	)

Other income (expense)
Amortization of intangible asset		(458,259	)		(458,259	)		(1,374,768	)		(1,374,772	)
Foreign currency transaction gain (loss)		(27,069	)		15,634			(39,968	)		60,004
Total other expense - net		(485,328	)		(442,625	)		(1,414,736	)		(1,314,768	)

Net loss	$	(1,152,042	)	$	(13,295,047	)	$	(37,810,674	)	$	(20,580,874	)

Loss per share - basic and diluted	$	(0.00	)	$	(0.03	)	$	(0.07	)	$	(0.04	)

Weighted average number of shares - basic and diluted		531,933,749			501,420,070			522,495,929			499,168,752

The accompanying notes are an integral part of these financial statements.

Table of Contents

INSTADOSE PHARMA CORP

STATEMENTS OF STOCKHOLDER DEFICITS

					Additional						Total
	Common Stock				Paid-in			Accumulated			Stockholders'
	Shares		Amount		Capital			Deficit			Equity

May 31, 2020		305,116,577		106,873,155		(1,182,536	)		(98,598,939	)		7,091,680

Retroactive application of recapitalization		190,940,653		19,094		(19,094	)					0

		496,057,230		106,892,249		(1,201,630	)		(98,598,939	)		7,091,680

Stock issued for services ($2/share)		4,846,279		9,692,559		0			0			9,692,559

Stock issued for services - related parties ($2/share)		4,000,000		8,000,000		0			0			8,000,000

Expensed paid on behalf of former subsidiary - related party						(26,823	)					(26,823	)

Net loss - 9 months ended - February, 2021		-		0		0			(20,580,874	)		(20,580,874	)

February 28, 2021		504,903,509		124,584,808		(1,228,453	)		(119,179,813	)		4,176,542

					Additional						Total
	Common Stock				Paid-in			Accumulated			Stockholders'
	Shares		Amount		Capital			Deficit			Equity (Deficit)

May 31, 2020		305,116,577	$	106,873,155	$	(1,153,743	)	$	(98,627,732	)	$	7,091,680

Retroactive application of recapitalization		190,940,653		19,094		(19,094	)

		496,057,230		106,892,249		(1,172,837	)		(98,627,732	)		7,091,680

Stock issued for services ($2/share)		6,723,423		13,446,846		0			0			13,446,846

Stock issued for services - related parties ($2/share)		7,772,856		15,545,712		0			0			15,545,712

Expensed paid on behalf of former subsidiary - related party		-		-		(42,636	)		-			(42,636	)

Net loss - 2021		-		0		0			(36,285,609	)		(36,285,609	)

May 31, 2021		510,553,509		135,884,807		(1,215,473	)		(134,913,341	)		(244,007	)

Stock issued for services ($2/share)		14,962,409		29,924,818		0			0			29,924,818

Stock issued for services - related parties ($2/share)		1,900,000		3,800,000		0			0			3,800,000

Debt Conversion		4,517,831		9,035,671		30,549,639						39,585,310

Recognition of stock based compensation		-		0		402,500			0			402,500

Net loss - 9 months ended - February 28, 2022		-		0		0			(37,810,674	)		(37,810,674	)

February 28, 2022		531,933,749	$	178,645,296	$	29,736,666		$	(172,724,015	)	$	35,657,947

The accompanying notes are an integral part of these financial statements.

Table of Contents

INSTADOSE PHARMA CORP

STATEMENTS OF CASH FLOWS

	Three Months Ended						Nine Months Ended
	February 28,						February 28,
	2022			2021			2022			2021
Operating activities
Net loss	$	(1,152,042	)	$	(13,295,047	)	$	(37,810,674	)	$	(20,580,874	)
Adjustments to reconcile net loss to net cash used in operations
Amortization of operating lease - right-of-use asset		24,258			24,258			72,774			72,775
Amortization of intangible rights		458,259			458,259			1,374,768			1,374,768
Common stock issued for services		0			5,660,644			29,924,818			9,692,559
Common stock issued for services - related parties		0			6,545,712			3,800,000			8,000,000
Recognition of stock based compensation								402,500			0
Changes in operating assets and liabilities
(Increase) decrease in
Prepaid and other current assets		739			(1,371	)		14,906			99,040
Increase (decrease) in
Accounts payable and accrued expenses		526,368			(229,662	)		2,707,644			(83,241	)
Accrued compensation - related parties		337,500			325,000			1,102,083			1,058,333
Operating lease liability		(34,639	)		(23,692	)		(84,448	)		(68,012	)
Net cash used in operating activities		160,443			(535,899	)		1,504,371			(434,652	)

Investing activities
Advances - related party		4,371			0			(803,189	)		(296,867	)
Advances - joint ventures		470			(237,966	)		(63,490	)		0
Purchase of equipment		0			0			(472,812	)		0
Net cash used in investing activities		4,841			(237,966	)		(1,339,491	)		(296,867	)

Financing activities
Advances - loan payable - related party		28,780			797,403			51,831			797,403
Repayments - loan payable - related party		0			0			(137,331	)		0
Additional Paid in Capital		(206,084	)					30,549,639
Debt Conversion		0			0			(39,693,970	)
Stock Issued for Debt Conversion								9,035,671
Stock issued for cash - net of offering costs of $0 and $22,500, respectively		0			0						0
Expensed paid on behalf of former subsidiary - related party		0			0			0			(26,817	)
Net cash provided by financing activities		(177,304	)		797,403			(194,160	)		770,586

Net increase (decrease) in cash		(12,020	)		23,538			(29,280	)		39,067

Cash - beginning of year		17,348			17,348			34,608			1,819

Cash - end of year	$	5,328		$	40,886		$	5,328		$	40,886

Supplemental disclosure of cash flow information
Cash paid for interest	$	0		$	0		$	0		$	0
Cash paid for income tax	$	0		$	0		$	0		$	0

The accompanying notes are an integral part of these financial statements.

Table of Contents

INSTADOSE PHARMA CORP. AND SUBSIDIARIES

~~(Formerly Mikrocoze Inc.)~~NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FEBRUARY 28, 2022

(UNAUDITED)

~~CONDENSED BALANCE SHEETS~~Note 1 - Organization and Nature of Operations

August 31,
2021

November 30,
2020

(Unaudited)

ASSETS

CURRENT ASSETS

Cash

$ 0

$ 65

TOTAL ASSETS

$ 0

$ 65

LIABILITIES AND STOCKHOLDERS’ DEFICIT

CURRENT LIABILITIES

Accounts payable

$ 24,259

$ 338

Due to related party

88,974

82,085

TOTAL CURRENT LIABILITIES

113,233

82,423

COMMITMENTS AND CONTINGENCIES

0

0

STOCKHOLDERS’ DEFICIT

Preferred stock, par value $0.0001, 1,000,000 shares authorized, 0 issued and outstanding

0

0

Common stock, par value $0.0001, 700,000,000 shares authorized, 75,000,000 and 75,000,000 shares issued and outstanding, respectively

7,500

7,500

Additional paid-in capital

98,585

16,500

Accumulated deficit

(219,318 )

(106,358 )

TOTAL STOCKHOLDERS’ DEFICIT

(113,233 )

(82,358 )

TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT

$ 0

$ 65

Organization and Nature of Operations

Instadose Pharma Corp (the “Company”), a Nevada corporation is organized as a holding company. The following business description describes the background and activities of its wholly owned subsidiary, Instadose Pharma Corp., a British Columbia corporation (“Instadose Canada”).

The ~~accompanying notes are~~Company, through its wholly owned subsidiary, Instadose Canada is seeking to create a global distribution platform for medicinal cannabis and cannabinoid oil (“Global Distribution Platform”). Instadose Canada endeavors to utilize the Global Distribution Platform to open the commercial gateway to a new wholesale marketplace capable of providing pharmaceutical industry companies (“Big Pharma”) with large, sustainable, consistent, diverse, and low‑cost supplies of high‑quality medicinal cannabis and cannabinoid oil for use in bulk as an ~~integral part~~active pharmaceutical ingredient.

Instadose Canada’s Global Distribution Platform spans five (5) continents to date, including Africa, Europe, Asia, South America, and North America. Within each continent, Instadose Canada is establishing large‑scale operational subsidiaries and joint venture partnerships to secure access to government‑issued licenses and permits in countries such as The Democratic Republic of the Congo (“DRC”), North Macedonia, Portugal, India, Colombia, Mexico, Cameroon, and Canada, each seeking to increase their level of participation within the global medicinal cannabis industry.

Instadose Canada was incorporated under the BCBCA as Cannabec Medical Corp. (“Cannabec”) on July 13, 2017, with an authorized share structure of 1,000 Class A common shares. On December 11, 2017, Cannabec filed a Form 11 Notice of Alteration with B.C. Registrar of Companies amending the authorized share structure to an unlimited number of common shares without par value, special rights, or restrictions. A Notice of Articles was issued by British Columbia Registry Services on the same date reflecting the amended share structure. On August 13, 2018, Cannabec changed its corporate name to Excellence Health Group Inc. (“EHG”). On January 31, 2019, EHG entered into a share exchange agreement with Grant F. Sanders and Instadose Canada. On February 5, 2019, EHG changed its corporate name to Instadose Pharma Corp. as contemplated by the share exchange agreement. The share exchange agreement was completed on February 8, 2019.

The EHG Share Exchange

Prior to completion of the share exchange, Grant F. Sanders, a former officer and director of the Company was actively engaged in seeking official authorization to cultivate medicinal cannabis in the DRC exclusively for medicinal and scientific purposes. Once secured, Instadose Canada would be granted exclusive rights to assist in monetizing these ~~condensed financial statements.~~medicinal cannabis rights. Pursuant to the terms of the share exchange, EHG agreed to acquire all of the issued and outstanding common shares of Instadose Canada from Mr. Sanders in exchange for EHG common shares. After the closing, EHG (as Instadose Canada) would carry on the business previously conducted by Instadose Canada. As a condition to completing the share exchange agreement, EHG agreed to cancel certain issued and outstanding EHG common shares following the EHG closing, as well as several outstanding stock options issued to EHG directors and officers.

Table of Contents

INSTADOSE PHARMA CORP. AND SUBSIDIARIES

~~(Formerly Mikrocoze Inc.)~~NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

~~CONDENSED STATEMENTS OF OPERATIONS~~FEBRUARY 28, 2022

(UNAUDITED)

Maribec

Three months ended
August 31,
2021

Three months ended
August 31,
2020

Nine months ended
August 31,
2021

Nine months ended
August 31,
2020

REVENUE

Product sales

$ 0

$ 0

$ 0

$ 0

Cost of goods sold

0

0

0

0

GROSS PROFIT

0

0

0

0

OPERATING EXPENSES

General and administrative

$ 2,704

$ 583

$ 14,275

$ 3,289

Professional fees

50,125

3,560

98,685

14,460

TOTAL OPERATING EXPENSES

(52,829 )

(4,143 )

(112,960 )

(17,749 )

NET LOSS

(52,829 )

(4,143 )

(112,960 )

(17,749 )

NET LOSS PER COMMON SHARE – BASIC AND DILUTED

$ (0.00 )

$ (0.00 )

$ (0.00 )

$ (0.00 )

WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING – BASIC AND DILUTED

75,000,000

75,000,000

75,000,000

75,000,000

Maribec Health Products Inc. (“Maribec”) is a Quebec corporation, which was registered with Registraire des Entreprises Québec on June 20, 2017. Following its registration, ownership of Maribec was held in the name of a director and officer of EHG pursuant to a declaration of trust in favour of EHG. On March 13, 2018, the declaration of trust was cancelled and ownership of Maribec was transferred to EHG. On December 20, 2017, Maribec, then a wholly owned subsidiary of EHG, submitted its application to Health Canada to become a licensed cannabis produce under the Access to Cannabis for Medical Purposes Regulations which would allow Maribec to establish operations at its production facility located at 433‑435 Boul. Industriel in the town of Asbestos (now Val‑des‑Sources), Quebec. Maribec’s license application would eventually be converted into an application for a standard cultivation license (under the new cannabis regulations which came into effect in Canada on October 17, 2018).

As at the date of the share exchange agreement, Maribec was still awaiting receipt of its cultivation license from Health Canada. On February 7, 2019, and prior to the EHG closing, EHG sold and transferred all of EHG’s right, title, and interest in and to the issued and outstanding shares of Maribec to Desmond Ste. Marie for one dollar ($1.00) pursuant to the terms of a share purchase agreement dated February 7, 2019. Completion of the Maribec Sale was driven by EHG’s desire to avoid potential delays in receiving its cultivation license that may have been caused by the pending completion of the share exchange. But for the Maribec Sale, completion of the share exchange would have required Health Canada to expand the scope of its due diligence screening to include the entirety of Instadose Canada’s incoming management team thereby almost certainly extending the timeline for Health Canada’s issuance of the cultivation license. Simultaneously with the execution of the Maribec share purchase agreement, EHG and Mr. Ste. Marie executed an option agreement also dated February 7, 2019. Pursuant to the terms of the option agreement, Mr. Ste. Marie granted to EHG an irrevocable option exercisable by EHG to re‑purchase the Maribec shares from Mr. Ste. Marie upon (i) EHG, its directors and officers obtaining the requisite consents, approvals, and security clearances from Health Canada and (ii) payment to Mr. Ste. Marie of one dollar. Under the option agreement, Instadose Canada was permitted to notify Mr. Ste. Marie of its desire to commence the process of exercising the option at any time.

On September 4, 2020, Health Canada issued the cultivation license to Maribec. The ~~accompanying notes are~~cultivation license is valid for three (3) years expiring on September 4, 2023. On October 2, 2020, Maribec submitted an ~~integral part~~application with Health Canada’s Cannabis Licensing and Security Division for a Standard Processing License under the Cannabis Regulations. The standard processing license was granted on February 25, 2021 and expires on September 4, 2023.

On March 11, 2021, Instadose Canada (formerly EHG) delivered the option notice to Mr. Ste. Marie regarding their election to exercise the option. To date, Instadose Canada has not completed that exercise. Instadose Canada will commence the process of ~~these condensed financial statements.~~obtaining all the Health Canada Approvals and completing their repurchase of Maribec in the second half off 2022.

Table of Contents

INSTADOSE PHARMA CORP. AND SUBSIDIARIES

~~(Formerly Mikrocoze Inc.)~~NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

~~CONDENSED STATEMENT OF STOCKHOLDERS’ DEFICIT~~

~~For the Three and Nine month periods ended August 31, 2021~~FEBRUARY 28, 2022

(UNAUDITED)

Common Stock

Additional

Number of
shares

Amount

Paid-in
Capital

Accumulated
Deficit

Total

Balance, November 30, 2020

75,000,000

$ 7,500

$ 16,500

$ (106,358 )

(82,358 )

Loan forgiveness – related party

-
��

0

82,085

82,085

Net loss for the period ended February 28, 2021

-

0

0

(12,169 )

(12,169 )

Balance, February 28, 2021

75,000,000

$ 7,500

$ 98,585

$ (118,527 )

$ (12,442 )

Net loss for the period ended May 31, 2021

-

0

0

(47,962 )

(47,962 )

Balance, May 31, 2021

75,000,000

$ 7,500

$ 98,585

$ (166,489 )

$ (60,404 )

Net loss for the period ended August 31, 2021

-

0

0

(52,829 )

(52,829 )

Balance, August 31, 2021

75,000,000

$ 7,500

$ 98,585

$ (219,318 )

$ (113,233 )

~~CONDENSED STATEMENTS OF STOCKHOLDERS’ DEFICIT~~

~~For the Three and Nine month period ended August 31, 2020~~

~~(UNAUDITED)~~Subsidiaries

Common Stock

Additional

Number of
shares

Amount

Paid-in
Capital

Accumulated
Deficit

Total

Balance, November 30, 2019

75,000,000

$ 7,500

$ 16,500

$ (80,701 )

$ (56,701 )

Net loss for the period ended February 29, 2020

-

0

0

(8,844 )

(8,844 )

Balance, February 29, 2020

75,000,000

$ 7,500

$ 16,500

$ (89,545 )

$ (65,545 )

Net loss for the period ended May 31, 2020

-

0

0

(4,762 )

(4,762 )

Balance, May 31, 2020

75,000,000

$ 7,500

$ 16,500

$ (94,307 )

$ (70,307 )

Ne Loss for the period ended August 31, 2020

(4,143 )

(4,143 )

Balance, August 31, 2020

75,000,000

$ 7,500

$ 16,500

$ (98,450 )

$ (74,450 )

~~The accompanying notes are an integral part of these condensed financial statements.~~Instadose Canada has the following subsidiaries

	(i)	Instadouz Farma Doo (“IDP Macedonia”);⁽¹⁾⁽²⁾;
6	(ii)	Instadose Pharma, LDA (“IDP Portugal”);⁽³⁾
	(iii)	Instadose Pharma India Private Limited (“IDP India”);⁽⁴⁾
	(iv)	IDP Holdings, Inc. (a wholly owned subsidiary); and
	(v)	IDP Canada Corp. (a wholly owned subsidiary).

____________

Notes:

⁽¹⁾IDP Macedonia is a North Macedonia company. Fifty percent (50%) ownership interest in IDP Macedonia is held by Grant F. Sanders as trustee for the Company pursuant to the terms of a trust declaration dated March 2, 2021.

⁽²⁾ IDP Macedonia operates the North Macedonia production facility. Ownership of the North Macedonia production facility is held in the name of Kanabiko Doo, Strumica (“Kanabiko”). Ownership of Kanabiko is registered fifty percent (50%) in the name of Grant F. Sanders as a trustee in trust for Instadose Canada on terms set out in a declaration of trust executed by Mr. Sanders on March 3, 2021. The remaining fifty percent (50%) ownership interest in Kanabiko is registered in the name of the North Macedonia partner.

⁽³⁾ Ninety‑five percent (95%) ownership interest in IDP Portugal is held by Aldo Vidinha and/or his personal corporation as trustee for Instadose Canada pursuant to the terms of a trust declaration dated March 4, 2021.

⁽⁴⁾ IDP India is an Indian company fifty-five percent (55%) owned by Instadose Canada. The remaining forty‑five percent (45%) equity ownership in IDP India is held by Instadose Canada’s joint venture partner in India, Sanctum Healthcare Remedies Private Limited.

Global Medicinal Cannabis Industry

Today’s global medicinal cannabis industry remains fractured as it struggles to define itself as a profitable and viable commercial business. The global production, sale, and distribution of medicinal cannabis and cannabinoid oil is monopolized by licensed producers with minimal participation to date from Big Pharma, who require sustainable, consistent, diverse, and low‑cost bulk supplies of high‑quality medicinal cannabis and cannabinoid oil to make entrance into the medicinal cannabis industry possible. Today’s licensed producers cannot meet the demands of Big Pharma due to several global challenges facing them. These challenges include the expensive cost of constructing and expanding indoor facilities, high manual labor costs, inefficient production process limiting product output, and strict government regulation limiting production capacity. In addition, there are substantial logistical challenges transporting medicinal cannabis from one international jurisdiction to another that require international policing authorities to participate in the process. Notwithstanding the foregoing, the demand for medicinal cannabis and cannabinoid oil continues to grow at a rapid pace. This is especially true as the rise in the volume of critical trials and scientific studies on medicinal cannabis and cannabinoid oil continue to uncover new and greater benefits to product consumption.

In Instadose Canada’s opinion, full participation in medicinal cannabis industry by Big Pharma will be required to satisfy the ever‑increasing global product demand, accelerate the volume of clinical trials and scientific studies aimed at uncovering new and greater benefits to medicinal cannabis and cannabinoid oil consumption, and unlock the market value potential of the medicinal cannabis industry predicted to reach US$ 84.0 Billion in market value by 2028¹. For this reason, Instadose Canada has committed to creating a large global distribution platform for medicinal cannabis and cannabinoid oil. Instadose Canada plans to utilize this global distribution platform to create a new wholesale marketplace and mass‑scale supply chain for medicinal cannabis and cannabinoid oil capable of providing Big Pharma with sustainable, consistent, diverse, and low‑cost supplies of high‑quality medicinal cannabis and cannabinoid oil for use in bulk as an active pharmaceutical ingredient.

Table of Contents

INSTADOSE PHARMA CORP. AND SUBSIDIARIES

~~(Formerly Mikrocoze Inc.)~~NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

~~CONDENSED STATEMENTS OF CASH FLOWS~~FEBRUARY 28, 2022

(UNAUDITED)

Nine-months ended
August 31,
2021

Nine-months ended
August 31,
2020

CASH FLOWS FROM OPERATING ACTIVITIES

Net loss for the period

$ (112,960 )

$ (17,749 )
Adjustments to reconcile net loss to net cash used in operating activities

Expenses paid on behalf of the Company by related party

88,974

12,046

Changes in operating assets and liabilities

Accounts payable

23,921

5,468

NET CASH USED IN OPERATING ACTIVITIES

(65 )

(235 )

CASH FLOWS FROM INVESTING ACTIVITIES

0

0

CASH FLOWS FROM FINANCING ACTIVITIES

Related party advances

0

330

NET CASH PROVIDED BY FINANCING ACTIVITIES

0

330

NET CHANGE IN CASH

(65 )

95

CASH, BEGINNING OF PERIOD

65

0

CASH, END OF PERIOD

$ 0

$ 95

SUPPLEMENTAL CASH FLOW INFORMATION AND NONCASH INVESTING AND FINANCING ACTIVITIES:

Cash paid during the period for:

Interest

$ 0

$ 0

Income taxes

$ 0

$ 0

Forgiveness of related party debt

$ 82,085

$ 0

Instadose Canada’s Global Distribution Platform spans five (5) Continents to date, including Africa, Europe, Asia, South America, and North America. Within each Continent, Instadose Canada is establishing large‑scale operational subsidiaries and joint venture partnerships to apply for and/or secure access to government‑issued licenses, permits, and joint venture partnerships. Currently, Instadose Canada is focused on securing licenses and establishing partnerships in the DRC, North Macedonia, Portugal, India, Colombia, Mexico, Cameroon, and Canada, each seeking to increase their level of participation within the global medicinal cannabis industry.

~~The accompanying notes~~____________

Notes:

¹ Grandview Research Inc. (March 2021) ‑ Legal Marijuana Market Worth $84.0 Billion by 2028 I CAGR 14.3% (https://www.grandviewresearch.com/press‑release/global‑legal‑marijuana‑market).

Global Distribution Platform

Instadose Canada is fueling the Global Distribution Platform by seeking to establish large-scale operational subsidiaries and joint venture partnerships (the “Participants”) throughout each continent engaging in medicinal cannabis cultivation and/or cannabinoid oil production. Participants engaged in medicinal cannabis cultivation are ~~an integral part~~responsible for growing, cultivating, packaging, and exporting medicinal cannabis to Participants engaged in cannabinoid oil production, whom, upon receipt of ~~these condensed financial statements.~~medicinal cannabis, sell it or utilize it in the production and sale of cannabinoid oil to pharmaceutical industry companies sourced by Instadose Canada or others.

Instadose Canada, as creator of the Global Distribution Platform, is responsible for the platform’s continued maintenance and growth. In doing so, Instadose Canada supplements the operational work performed by Global Distribution Platform Participants by performing the following key functions:

	(i)	Organizing, managing, and sourcing the transport of medicinal cannabis from medicinal cannabis cultivation Participants to one or more cannabinoid oil production participants;
7	(ii)	Selling all medicinal cannabis and cannabinoid oil cultivated and/or produced by Global Distribution Platform Participants to pharmaceutical industry companies; and
	(iii)	Sourcing new medicinal cannabis cultivation and cannabinoid oil production Participants across new and existing Continents.

The Transportation of Medicinal Cannabis throughout the Global Distribution Platform

The ability to transport medicinal cannabis safely and efficiently from one continent to another throughout the Global Distribution Platform is a critical component of Instadose Canada’s global business model. On January 6, 2021, Instadose Canada entered into a three-year logistics and procurement services agreement with Project Management Resources Inc. (“PMR”), a Canadian company. Since 1993, the principals of PMR have been actively involved in the transportation of goods within the African Continent. Under the Logistics and Procurement Services Agreement, PMR agreed to assume all responsibility for the management and procurement of those services required for, among other things, the international warehousing, customs clearing, and transportation of medicinal cannabis in and from, among other continents, Africa, Europe, South America, Asia and North America. PMR also agreed to perform the logistics and procurement services exclusively for Instadose Canada to the exclusion of any other company participating in medicinal cannabis industry. Payment for all logistics and procurement services is made by Instadose Canada to PMR on a fixed rate basis in accordance with applicable industry standards.

The Logistics and Procurement Services Agreement is supported by individual independent consulting agreements dated January 6, 2021, entered into between Instadose Canada and PMR principals.

Table of Contents

INSTADOSE PHARMA CORP. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FEBRUARY 28, 2022

(UNAUDITED)

Risk Mitigation Strategies

Instadose Canada is in the process of implementing numerous risk mitigation strategies to protect the company from events of force majeure as well as other possible risks affecting Instadose Canada’s business model. These strategies include the following:

~~INSTADOSE PHARMA CORP.~~	~~(Formerly Mikrocoze Inc.)~~(i)	~~NOTES TO CONDENSED FINANCIAL STATEMENTS~~Requiring, where feasible, Global Distribution Platform Participants to purchase insurance to protect against items such as, but not limited to, crop loss, political risk, equipment and casualty, and equipment breakdown;
~~AUGUST 31, 2021 (Unaudited)~~	(ii)	Establishing large reserves of medicinal cannabis and cannabinoid oil to be stored at cannabinoid oil production facilities;
	(iii)	Requiring pharmaceutical industry companies to complete payment in full for all purchased medicinal cannabis and cannabinoid oil prior to its release ex‑works from the applicable cannabinoid oil production facilities;
	(iv)	Maintaining control of the business relationship with all pharmaceutical industry companies as well as the flow of funds for all purchase orders of medicinal cannabis and cannabinoid oil;
	(v)	Establishing and maintaining geographic diversity for medicinal cannabis cultivation and cannabinoid oil production in an effort to avoid reliance on any one particular country or continent; and
	(vi)	Engaging in extensive due diligence on pharmaceutical industry companies, joint venture partners, and existing political climates.

Notwithstanding Instadose Canada’s efforts to mitigate risk at all levels of its business operations, certain situations can arise where Instadose Canada will be required to terminate, or delay the commencement of a joint venture agreement, or terminate, or delay the commencement of a purchase or supply agreement.

Participant Activities by Continent

The following chart summarizes those Participant activities (i.e., medical cannabis cultivation and/or cannabinoid oil production) in the process of being or to be conducted on behalf of Instadose Canada and the Global Distribution Platform within each Continent:

Continent	Countries of Operation	Operational Activity	Participant Relationship
Africa	DRC	Medicinal Cannabis Cultivation	Joint Venture Partnership
Africa	Cameroon	Medicinal Cannabis Cultivation	Joint Venture Partnership
Europe	North Macedonia	Cannabinoid Oil Production	Subsidiary
Europe	Portugal	Cannabinoid Oil Production	Subsidiary
Asia	India	Both	Subsidiary
South America	Colombia	Medicinal Cannabis Cultivation	Joint Venture Partnerships
North America	Mexico	Both	Joint Venture Partnership⁽¹⁾
North America	Canada	Cannabinoid Oil Production	Operating Subsidiary⁽²⁾

Notes:

____________

⁽¹⁾ Final structure is subject to change.

⁽²⁾ Following the repurchase of Maribec.

~~NOTE 1 – NATURE OF OPERATIONS~~Impact of COVID-19

The ongoing COVID-19 global and national health emergency has caused significant disruption in international economies and financial markets. In March 2020, the World Health Organization declared the COVID-19 outbreak a pandemic. The spread of COVID-19 has caused illness, quarantines, cancellation of events and travel, business and school shutdowns, reduction in business activity and financial transactions, labor shortages, supply chain interruptions and overall economic and financial market instability. The COVID-19 pandemic has the potential to significantly impact the Company’s supply chain, distribution centers, or logistics and other service providers.

Table of Contents

INSTADOSE PHARMA CORP. AND ~~BASIS OF PRESENTATION~~SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FEBRUARY 28, 2022

(UNAUDITED)

~~Mikrocoze Inc. was incorporated~~In addition, a severe prolonged economic downturn could result in a variety of risks to the ~~State of Nevada as~~business, including weakened demand for products and services and a ~~for-profit Company~~decreased ability to raise additional capital when needed on ~~August 17, 2016 and established a fiscal year end of November 30. The Company was organized~~acceptable terms, if at all. As the situation continues to ~~sell micro-furniture that is designed to maximize any small space and to sell its products via the internet.~~

~~On October 9, 2020, the existing director and officer of~~evolve, the Company ~~resigned effective immediately. Accordingly, Sukhmanjit Singh, serving as a director~~will continue to closely monitor market conditions and an officer, ceased to be the Company’s Chief Executive Officer, Chief Financial Officer, President, Treasurer, Secretary and a Director. At the effective date of the resignation, Mr. Terry Wilshire consented to act as the new President and Member of the Board of Directors of the Company and Robert Dickenson consented to act as the new Vice President and Member of the Board of Directors of the Company.

On March 4, 2021, Mikrocoze, Inc. filed a Certificate of Amendment with the Secretary of State of Nevada effecting a name change on March 11, 2021 to Instadose Pharma Corp. Further on March 11, 2021, the Financial Industry Regulatory Authority approved the name change and trading symbol to “INSD”. InstadosePharma Corp is now focused on growth and acquisition of pharmaceutical grade agricultural products.

~~Going concern~~respond accordingly.

To date, ~~the Company has generated minimal revenues from its~~we have maintained uninterrupted business operations with normal turnaround times for servicing our customers. We have implemented adjustments to our operations designed to keep employees safe and ~~has incurred operating losses since inception of $219,318. As at August 31, 2021, the Company has a working capital deficit of $113,233.~~comply with federal, state, and local guidelines, including those regarding social distancing. The ~~Company will require additional funding~~extent to meet its ongoing obligations and to fund anticipated operating losses. The ability of the Company to continue as a going concern is dependent on raising capital to fund its initial business plan and ultimately to attain profitable operations. Accordingly, these factors raise substantial doubt as towhich COVID19 may further impact the Company’s ~~ability~~business, results of operations, financial condition and cash flows will depend on future developments, which are highly uncertain and cannot be predicted with confidence. In response to ~~continue as a going concern for a period of one year from~~COVID-19, the ~~issuance of these~~United States government has passed legislation and taken other actions to provide financial ~~statements. The Company intends~~relief to ~~continue to fund its business~~companies and other organizations affected by ~~way of private placements and advances from related parties as may be required. These financial statements do not include any adjustments relating to~~ the ~~recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might result from this uncertainty.~~pandemic.

~~NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES~~The ultimate impact of the COVID-19 pandemic on the Company’s operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak, new information which may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced customer traffic and reduced operations.

Any resulting financial impact cannot be reasonably estimated at this time but is anticipated to have a material adverse impact on our business, financial condition, and results of operations.

Basis of Presentation ~~– Unaudited Financial Statements~~

The consolidated financial statements have been presented in Canadian dollars and are prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).

Instadose Pharma Corp. has determined that the Canadian dollar is the most relevant and appropriate reporting currency as, despite continuing shifts in the relative size of our operations across multiple geographies, the majority of our operations are conducted in Canadian dollars and our financial results are prepared and reviewed internally by management in Canadian dollars.

The accompanying unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles for financial information and with the instructions to Form 10-Q. They do not include all information and footnotes required by United States generally accepted accounting principles for complete financial statements. However, except as disclosed herein, there has been no material changes in the information disclosed in the notes to the consolidated financial statements for the fiscal year ended ~~November 30, 2020~~May 31, 2021 included in the Company’s year-end consolidated financial statements on Form ~~10-K~~8-K filed by Instadose Pharma Corp. (formerly known as Mikrocoze, Inc.), filed with the United States Securities and Exchange Commission. The unaudited financial statements should be read in conjunction with those financial statements included in the Form ~~10-K.~~ 8-K.

In the opinion of Management, all adjustments considered necessary for a fair presentation, consisting solely of normal recurring adjustments, have been made. Operating results for the ~~three and~~ nine months ended ~~August 31, 2021~~February 28, 2022, are not necessarily indicative of the results that may be expected for the year ending ~~November 30, 2021.~~

~~Use of Estimates and Assumptions~~

Preparation of the financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Accordingly, actual results could differ from those estimates.

~~Cash and Cash Equivalents~~

~~For purposes of the statement of cash flows, the Company considers highly liquid financial instruments purchased with a maturity of three months or less to be cash equivalents.~~May 31, 2022.

~~Table of Contents~~

~~INSTADOSE PHARMA CORP.~~

~~(Formerly Mikrocoze Inc.)~~

~~NOTES TO CONDENSED FINANCIAL STATEMENTS~~

~~AUGUST 31, 2021 (Unaudited)~~

~~NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)~~

~~Revenue Recognition~~

The Company recognizes revenue in accordance with ASC topic 606 “Revenue from contracts with customers, and other applicable revenue recognition guidance under US GAAP. Sales revenue is recognized for our retail and wholesale customers when: (i) approval of both parties, (ii) the goods or services associated with transaction must be identified, (iii) identification of

the transaction price, (iv) the contract has commercial substance, and (v) the performance obligation is satisfied — generally when products are shipped to the customer. Revenues to consists of revenue earned from the sale of medical grade agricultural products and is recognized at the time the product is shipped to the customer.

~~Fair Value of Financial Instruments~~

~~The carrying amount of the Company’s financial assets and liabilities approximates their fair values due to their short-term maturities.~~

~~Loss per Common Share~~

The basic loss per share is calculated by dividing the Company’s net loss available to common shareholders by the weighted average number of common shares during the year. The diluted loss per share is calculated by dividing the Company’s net loss available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted for any potentially dilutive debt or equity. Diluted loss per share is the same as basic loss per share due to the lack of dilutive items in the Company. As of August 31, 2021 and August 31, 2020, there were no common stock equivalents outstanding.

~~Income Taxes~~

The Company follows the liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax balances and tax loss carry-forwards. Deferred tax assets and liabilities are measured using enacted or substantially enacted tax rates expected to apply to the taxable income in the years in

which those differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the date of enactment or substantive enactment.

~~Stock-based Compensation~~

The Company follows ASC 718-10, "Stock Compensation", which addresses the accounting for transactions in which an entity exchanges its equity instruments for goods or services, with a primary focus on transactions in which an entity obtains employee services in share-based payment transactions. ASC 718-10 is a revision to SFAS No. 123, "Accounting for Stock-Based Compensation," and supersedes Accounting Principles Board ("APB") Opinion No. 25, "Accounting for Stock Issued to Employees," and its related implementation guidance. ASC 718-10 requires measurement of the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award (with limited exceptions). Incremental compensation costs arising from subsequent modifications of awards after the grant date must be recognized. The Company has not adopted a stock option plan and has not granted any stock options. As at August 31, 2021 the Company had not adopted a stock option plan nor had it granted any stock options. Accordingly, no stock-based compensation has been recorded to date.

~~Recent Accounting Pronouncements~~

~~The Company does not expect the adoption of any recent accounting pronouncements to have a material impact on its financial statements.~~

~~Table of Contents~~

~~INSTADOSE PHARMA CORP.~~

~~(Formerly Mikrocoze Inc.)~~

~~NOTES TO CONDENSED FINANCIAL STATEMENTS~~

~~AUGUST 31, 2021 (Unaudited)~~

~~NOTE 3 – CAPITAL STOCK~~

The Company is authorized to issue 700,000,000 common shares with a par value of $0.0001 per share. The Company is authorized to issue 1,000,000 preferred shares with a par value of $0.0001. There were no issuances of common stock during the current period. The change in par value has been retroactively re-stated for all periods presented.

On December 23, 2020, Mikrocoze, Inc. (the “Company”) filed a Certificate of Amendment to its Articles of Incorporation (the “Certificate of Amendment”) with the Secretary of State of the State of Nevada increasing the authorized shares of common stock, par value $0.001 to 500,000,000.

On June 10, 2021, Instadose Pharma Corp. (the “Company”), filed with the Secretary of State of the State of Nevada an amendment to its articles of incorporation (the “Amendment”) to increase the authorized common stock from 500,000,000 shares to 700,000,000 shares, par value $.0001 per share. The Amendment also authorized the Company to issue up to 1,000,000 shares of blank check preferred stock, par value $.0001 per share. The financial statements have been retroactively re-stated to show the change in par value.

~~During the period the Company agreed to sell 1,000 shares of the Company’s common stock at $1.00 per share to 10 shareholders. No cash was received and shares were issued subsequent to the period.~~

~~NOTE 4 – RELATED PARTY TRANSACTIONS~~

During the period ended August 31, 2021, the CEO paid expenses of $45,974 on behalf of the Company. The total amount owed to the CEO as of August 31, 2021, was $88,974 (November 30, 2020 - $82,085- owed by the previous CEO), which includes $43,000 in accrued management fees. The amounts due to related parties are unsecured and non-interest-bearing with no set terms of repayment.

On February 28, 2021, the former CEO of the Company forgave all related party loans to the Company totaling $82,085. This was reflected as an increase in Additional-Paid-In-Capital in the financial statements.

On March 30, 2021, Instadose Pharma Corp. (the “Company”) entered into an executive employment agreement (the “Agreement”) with the Company’s President, Terry Wilshire, effective as of April 15, 2021 (the “Executive”), pursuant to which Mr. Wilshire will continue to serve in such position. Pursuant to the terms of the Agreement, the employment of Executive terminates on December 31, 2021, but the term automatically extends year to year thereafter unless earlier terminated by either party not later than thirty (30) days prior to December 31st.

In consideration therefore, Executive will be paid a base salary of $8,000 per month. Said base salary shall not be decreased without his prior written consent. Executive will also receive a $600 car allowance (together with the monthly salary, the “Base Salary”).

Upon termination by Executive of his employment for good reason or by the Company for any reason other than for “cause”, the Executive shall be entitled to his Base Salary through the end of the applicable term of the Agreement. Cause is defined in the Agreement as, among others, any act or omission that constitutes a material breach which is not cured following notice by the Company and the willful and continued refusal of Executive to satisfactorily perform his duties, which failure continues after notice and the conviction of any felony or crime involving dishonesty.

The Employment Agreement contains customary confidentiality provisions during and after the term of employment of Executive. Executive also agreed that during the term of his employment with the Company and for one year thereafter he will not engage in any business which competes with the business of the Company. As of August 31, 2021 the Company owed the CEO $43,000 in management fees.

~~Table of Contents~~

~~INSTADOSE PHARMA CORP.~~

~~(Formerly Mikrocoze Inc.)~~

~~NOTES TO CONDENSED FINANCIAL STATEMENTS~~

~~AUGUST 31, 2021 (Unaudited)~~

~~NOTE 5 – SUBSEQUENT EVENTS~~

~~Plan of Arrangement~~

On September 1, 2021, Instadose Pharma Corp., a Nevada corporation (the “Company”), entered into a plan of arrangement (the “Agreement”) with Instadose Pharma Corp., a corporation organized under the laws of Canada (“Instadose”). Upon the satisfaction of the conditions set forth in the Agreement, the Company will acquire all of the issued and outstanding shares of

~~common stock (the “Shares”) of Instadose. The consideration to be paid for each Share shall be 1.34 shares of common stock of the Company.~~

Instadose is building a large-scale commercial outdoor growing, cultivation, production, and global distribution platform (the “Global Distribution Platform”) for medicinal cannabis and cannabinoid oil. Utilizing the Global Distribution Platform, Instadose will be seeking to open the commercial gateway to a new wholesale marketplace capable of providing pharmaceutical industry companies with large, sustainable, consistent, diverse, and low‑cost supplies of high‑quality medicinal cannabis and cannabinoid oil for use in bulk as an active pharmaceutical ingredient.

Instadose’s Global Distribution Platform spans five (5) world continents to date, including Africa, Europe, Asia, South America, and North America (each, a “Continent”). Within each Continent, Instadose is establishing operational subsidiaries and joint venture partnerships to secure access to government-issued licenses and permits in countries such as The Democratic Republic of the Congo, the Republic of North Macedonia, the Portuguese Republic, the Republic of India, Colombia, Mexico, and Canada, each seeking to increase their level of participation within the global Medicinal Cannabis industry.

~~Upon consummation of the transaction, the Company will no longer be considered a “shell” company.~~

~~Based on information provided to the Company, at the closing the Company will have to issue an aggregate of 463,754,949 shares of common stock of the Company to the Instadose shareholders.~~

Upon the completion of the transaction contemplated by the Agreement, the Board of Directors of the Company shall include three directors identified by Instadose and two directors identified by the Company. Subject to requisite approvals and applicable law, the Board of Directors of the Company shall consist of Grant F. Sanders, Alex Wylie, Lt. General (ret’d) the Honourable Andrew Leslie, Ann Barnes, and Peter Wirth. The management team of the Company after closing will consist of (i) Grant F. Sanders, Chairman of the Board; (ii) Lawrence M. Acton, Chief Operating Officer; (iii) Loren S. Greenspoon, Chief Strategy Officer and Canadian Legal Counsel; (iv) Alex Wylie, Chief Financial Officer; (v) Terry Wilshire, Chief Risk Officer; (vi) Andres Victoria, VP, Latin America Operations; (vii) Andrew Baukham, VP, Global Logistics; and (viii) Gareth Wiggan, Manager of African Operations.

~~Shareholders of Instadose who properly dissent to the transaction at least two days prior to the shareholders meeting shall be entitled to receive the fair value of their shares from the Company.~~

The Agreement can be terminated by either party if (i) the closing does not occur on or before December 31, 2021, (ii) the shareholders of Instadose do not approve the transaction with the Company or (iii) if the Agreement is deemed illegal. The Company may terminate the Agreement if Instadose is in breach of the terms of the Agreement or any event occurs such that Instadose will be unable to fulfill its obligations under the Agreement by December 31, 2021. Instadose may terminate the Agreement if the Company is in breach of the terms of the Agreement, if Instadose receives a superior offer, or if any event occurs such that the Company will be unable to fulfill its obligations under the Agreement by December 31, 2021.

~~Table of Contents~~

~~INSTADOSE PHARMA CORP.~~

~~(Formerly Mikrocoze Inc.)~~

~~NOTES TO CONDENSED FINANCIAL STATEMENTS~~

~~AUGUST 31, 2021 (Unaudited)~~

~~NOTE 5 – SUBSEQUENT EVENTS (continued)~~

The Special Committee of the Board of Directors of Instadose received a fairness opinion from IJW & Co., Ltd., its financial advisor, that the consideration to be received by the shareholders of Instadose pursuant to the Arrangement is fair from a financial point of view to said shareholders.

The foregoing description of the Agreement and the transactions contemplated thereby does not purport to be complete and is subject to, and qualified in its entirety by reference to, the Plan of Arrangement, a copy of which is attached as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference. Please refer to the 8-K filed by Company with SEC on September 22, 2021.

~~Share Issuance~~

Subsequent to the period the Company agreed to sell an additional 200 shares of the Company’s common stock at $1.00 per share to 2 shareholders. The $1,200 in cash was received for all 10 shareholders during the period and 2 shareholders from subsequent period and all 1,200 shares were issued subsequent to the period.

~~Table of Contents~~

~~Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.~~

This section of this Form 10-Q includes a number of forward-looking statements that reflect our current views with respect to future events and financial performance. Forward-looking statements are often identified by words like believe, expect, estimate, anticipate, intend, project and similar expressions, or words which, by their nature, refer to future events. You should not place undue certainty on these forward-looking statements. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from our predictions.

On October 9, 2020, the existing director and officer of the Company resigned effective immediately. Accordingly, Sukhmanjit Singh, serving as a director and an officer, ceased to be the Company’s Chief Executive Officer, Chief Financial Officer, President, Treasurer, Secretary and a Director. At the effective date of the resignation, Mr. Terry Wilshire consented to act as the new President and Member of the Board of Directors of the Company and Robert Dickenson consented to act as the new Vice President and Member of the Board of Directors of the Company.

~~Plan of Arrangement~~

~~Upon consummation of the transaction, the Company will no longer be considered a “shell” company.~~

~~Based on information provided to the Company, at the closing the Company will have to issue an aggregate of 463,754,949 shares of common stock of the Company to the Instadose shareholders.~~

Table of Contents

~~Shareholders~~INSTADOSE PHARMA CORP. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FEBRUARY 28, 2022

(UNAUDITED)

Liquidity, Going Concern and Management’s Plans

These consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of ~~Instadose who properly dissent~~assets and the settlement of liabilities and commitments in the normal course of business.

As reflected in the accompanying consolidated financial statements, for the nine months ended February 28, 2022, the Company had:

·	Net loss of $37,810,674; and
·	Net cash used in operations was $1,504,372

Additionally, at February 28, 2022, the Company had:

·	Accumulated deficit of $172,724,015
·	Retained Earnings of $35,657,946; and
·	Working capital deficit of $10,110,799

We manage liquidity risk by reviewing, on an ongoing basis, our sources of liquidity and capital requirements. The Company has cash on hand of $5,328 at February 28, 2022.

Once business operations commence during fiscal year end May 31, 2023, the Company expects to generate sufficient revenues and positive cash flows from operations to meet its current obligations. However, the Company may seek to raise debt or equity-based capital at favorable terms, though such terms are not certain. Currently, the Company expects to incur losses from operations and have negative cash flows from operating activities for the near-term.

See Note 9 regarding the conversion of loan payable with the Company’s Former Chairman and Chief Executive Officer totaling $39,531,029.

As the Company begins its business operations, we note that in recent years, the actions of governments around the world have signaled a significant change in attitudes towards cannabis, have either formally legalized medical cannabis access or established government efforts to explore the legalization of medical cannabis access. Therefore, opportunities continue to exist for the Company to operate in jurisdictions where governments have established, or are actively moving towards, a legal framework.

These factors create substantial doubt about the Company’s ability to continue as a going concern within the twelve-month period subsequent to the ~~transaction at least two days prior to the shareholders meeting shall be entitled to receive the fair value of their shares from the Company.~~

date that these consolidated financial statements are issued. The ~~Agreement can be terminated by either party if (i) the closing does not occur on or before December 31, 2021, (ii) the shareholders of Instadose~~consolidated financial statements do not ~~approve the transaction with the Company or (iii) if the Agreement is deemed illegal. The Company may terminate the Agreement if Instadose is in breach of the terms of the Agreement or~~include any ~~event occurs such~~adjustments that ~~Instadose will~~might be ~~unable to fulfill its obligations under the Agreement by December 31, 2021. Instadose may terminate the Agreement~~necessary if the Company is ~~in breach of~~unable to continue as a going concern. Accordingly, the ~~terms of the Agreement, if Instadose receives~~consolidated financial statements have been prepared on a ~~superior offer, or if any event occurs such~~basis that assumes the Company will ~~be unable to fulfill its obligations under~~continue as a going concern and which contemplates the ~~Agreement by December 31, 2021.~~realization of assets and satisfaction of liabilities and commitments in the ordinary course of business.

~~The Special Committee of~~Management’s strategic plans include the Board of Directors of Instadose received a fairness opinion from IJW & Co., Ltd., its financial advisor, that the consideration to be received by the shareholders of Instadose pursuant to the Arrangement is fair from a financial point of view to said shareholders.

~~Results of Operations~~

~~For the three-month period ended August 31, 2021 and August 31, 2020 we had no revenues, or cost of goods sold.~~

Expenses for the three-month period ended August 31, 2021 totaled $52,829 resulting in a net loss of $52,829. The net loss for the three-month period ended August 31, 2021 is the result of expenses of $52,829, comprised of professional fees of $50,125, which includes $25,800 in management fees; transfer agent expenses of $782; filing fees of $1,917; and bank service charges of $5. Expenses for the three-month period ended August 31, 2020 totaled $4,143 resulting in a net loss of $4,143. The net loss for the three-month period ended August 31, 2020 is the result of expense of $4,143, comprised of professional fees of $3,560; transfer agent expenses of $234; rent expenses of $262; telephone expense of $38; and bank service charges of $49. The increase in expenses between August 31, 2021 and August 31, 2020 is primarily due to the increase in professional fees due to the implementation of management fees during the period and an increase in legal fees.

~~For the nine-month period ended August 31, 2021 and August, 2020 we had no revenues, or cost of goods sold.~~

Expenses for the nine-month period ended August 31, 2021 totaled $112,960 resulting in a net loss of $112,960. The net loss for the nine-month period ended August 31, 2021 is the result of expenses of $112,960, comprised of professional fees of $98,685, which includes $43,000 in management fees; transfer agent expenses of $5,445; filing fees of $8,765; and bank service charges of $65. Expenses for the nine-month period ended August 31, 2020 totaled $17,749 resulting in a net loss of $17,749. The net loss for the nine-month period ended August 31, 2020 is the result of expense of $17,749, comprised of professional fees of $14,460; filing fees of $573; transfer agent expenses of $1,610; rent expenses of $738; telephone expense of $166; and bank service charges of $202. The increase in expenses between August 31, 2021 and August 31, 2020 is primarily due to the increase in professional fees due to the implementation of management fees, an increase in legal fees, and the Company making application to list with OTC Markets.

~~Liquidity and Capital Resources~~

We have generated minimal revenues to date and anticipate until we generate a more rapid growth in revenues, we will require additional financings in order to fully implement our plan of operations. With the exception of cash advances from our sole Officer and Director, and cash received in our initial offering, we have not had any additional funding. We must raise cash to implement our strategy and stay in business. Our president has verbally committed to continue to fund our operations up to $75,000. However, this is not in writing and maybe rescinded at any time.

As of August 31, 2021, we had $nil in cash and $88,974 due to a related party. As of November 30, 2020, we had 65 in cash, and $82,085 due to a related party, the former president/director of the Company . Total liabilities as of August 31, 2021, were $113,233 compared to $82,423 at November 30, 2020. The funds available to the Company will not be sufficient to fund the planned operations of the Company and maintain a reporting status. As of August 31, 2021, the Company owed $88,974 (November 30, 2020; $82,085 owed to the previous CEO of the Company) to its current Chief Executive Officer. During the nine-month period ended August 31, 2021 and 2020, the CEO paid expenses of $45,974 (and accrued management fees of $43,000) and $9,410, respectively, on behalf of the Company. All amounts due to the related party are unsecured, non-interest bearing and have no set terms of repayment.following:

·	Execute business operations during fiscal year May 31, 2022, and 2023;
·	Create new joint venture relationship partners and operating subsidiaries throughout the world in order to expand the Global Distribution Platform to new geographical markets;
·	Continue to secure new supply agreements from pharmaceutical industry companies for Medicinal Cannabis and Cannabinoid Oil; and

Risks and Uncertainties

In general, the following represents a non-exhaustive listing of some, but not all, expected future risks and uncertainties related to the Cannabis industry:

·	Operating in a highly regulated industry where the regulatory environments are rapidly developing, and we may not always succeed in complying fully with applicable regulatory requirements in all jurisdictions where we carry on business.
·	We and our joint ventures and strategic investments are reliant on required licenses, authorizations, approvals and permits for our ability to grow, process, store and sell cannabis which are subject to ongoing compliance, reporting and renewal requirements and we may also be required to obtain additional licenses, authorizations, approvals and permits in connection with our business.
·	Changes in the laws, regulations and guidelines governing cannabis and U.S. hemp may adversely impact our business.
·	We are constrained by law in our ability to market and advertise our products.
·	We could be adversely affected by violations of the Corruption of Foreign Public Officials Act (Canada), the U.S. Foreign Corrupt Practices Act and other similar anti-bribery laws.

Table of Contents

~~On February~~INSTADOSE PHARMA CORP. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FEBRUARY 28, ~~2021, the former CEO of the Company forgave all related party loans to the Company totaling $82,085. This was reflected as an increase in Additional-Paid-In-Capital in the financial statements.~~

2022

~~Off-balance sheet arrangements~~(UNAUDITED)

Other than the situation described in the section titled Capital Recourses and Liquidity, the company has no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect or change on the company’s financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors. The term “off-balance sheet arrangement” generally means any transaction, agreement or other contractual arrangement to which an entity unconsolidated with the company is a party, under which the company has (i) any obligation arising under a guarantee contract, derivative instrument or variable interest; or (ii) a retained or contingent interest in assets transferred to such entity or similar arrangement that serves as credit, liquidity or market risk support for such assets.

~~Item 3. Quantitative and Qualitative Disclosures about Market Risk.~~

~~We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.~~

~~Item 4. Controls and Procedures.~~

~~Disclosure Controls and Procedures~~

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported, within the time period specified in the SEC's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed or submitted under the Securities Exchange Act of 1934 is accumulated and communicated to management including our principal executive officer and principal financial officer as appropriate, to allow timely decisions regarding required disclosure.

In connection with this quarterly report, as required by Rule 15d-15 under the Securities Exchange Act of 1934, we have carried out an evaluation of the effectiveness of the design and operation of our company's disclosure controls and procedures. This evaluation was carried out under the supervision and with the participation of our company's management, including our company's principal executive officer and principal financial officer. Based upon that evaluation, our company's principal executive officer and principal financial officer concluded that subject to the inherent limitations noted in this Part II, Item 9A(T) as of August 31, 2021, our disclosure controls and procedures were not effective due to the existence of material weaknesses in our internal controls over financial reporting.

~~Changes in Internal Control Over Financial Reporting~~

There were no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) or 15d-15(f)) during the quarter ended August 31, 2021 that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

·	Cannabis is a controlled substance in the United States and therefore subject to the Controlled Substances Import and Export Act.
·	We will be subject to a number of federal, state, and foreign environmental and safety laws and regulations that may expose us to significant costs and liabilities.
·	Anti-money laundering and other banking laws and regulations can limit our ability to access financing and hamper our growth.
·	There is limited long-term data with respect to the efficacy and side effects of our products and future clinical research studies on the effects of cannabis, hemp and cannabinoids and cannabis-based products may lead to conclusions that dispute or conflict with our understanding and belief regarding their benefits, viability, safety, efficacy, dosing, and social acceptance.
·	Controlled substance and other legislation and treaties may restrict or limit our ability to research, manufacture and develop a commercial market for our products outside of the jurisdictions in which we currently operate and our expansion into such jurisdictions is subject to risks.
·	Investments and joint ventures outside of Canada and the United States are subject to the risks normally associated with any conduct of business in foreign countries, including varying degrees of political, legal, and economic risk.
·	There can be no assurance that our current and future acquisitions, strategic alliances, investments, or expansions of scope of existing relationships will have a beneficial impact on our business, financial condition, and results of operations.
·	We are subject to risks relating to our current and future operations in emerging markets.
·	We may not be able to achieve or maintain profitability and may continue to incur losses in the future.
·	We may be subject to product liability claims.
·	We are highly dependent on our senior management, specifically, our Chairman and Chief Executive Officer.
·	We will seek to maintain adequate insurance coverage in respect of the risks we face, however, insurance premiums for such insurance may not continue to be commercially justifiable and there may be coverage limitations and other exclusions which may not be sufficient to cover our potential liabilities.
·	Fluctuations in wholesale and retail prices could result in earnings volatility.
·	Infectious Diseases and Global Virus Outbreaks.

Note 2 - Summary of Significant Accounting Policies

Use of Estimates

Preparing financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reported period. Actual results could differ from those estimates, and those estimates may be material.

Significant estimates during the nine months ended February 28, 2022, and 2021 include the borrowing rate considered for operating lease right-of-use asset and related operating lease liability, valuation of intangible rights – related party, uncertain tax positions, and the valuation allowance on deferred tax assets.

Principles of Consolidation and Non-Controlling Interest

These consolidated financial statements have been prepared in accordance with U.S. GAAP and include the accounts of the Company and both its wholly owned and majority-owned subsidiaries. All intercompany transactions and balances have been eliminated.

Non-controlling interest is recorded in total stockholders’ deficit in the consolidated financial statements. For the nine months ended February 28, 2022, and 2021, none of the Company’s subsidiaries were operational, as a result, non-controlling interest has a balance of $0.

Table of Contents

~~PART II—OTHER INFORMATION~~INSTADOSE PHARMA CORP. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FEBRUARY 28, 2022

(UNAUDITED)

Variable Interest Entities

A variable interest entity (“VIE”) is an entity that does not have sufficient equity at risk to finance its activities without additional subordinated financial support or is structured such that equity investors lack the ability to control the entity’s activities or do not substantially participate in the gains and losses of the entity. Upon inception of a contractual agreement, and thereafter, if a reconsideration event occurs, the Company performs an assessment to determine whether the arrangement contains a variable interest in an entity and whether that entity is a VIE. The primary beneficiary of a VIE is the party that has both the power to direct the activities that most significantly impact the VIE’s economic performance and the obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE. Under Accounting Standards Codification (“ASC”) 810 – Consolidations, where the Company concludes that it is the primary beneficiary of a VIE, the Company consolidates the accounts of that VIE. At February 28, 2022 and May 31, 2021, respectively, the Company has no VIE’s.

~~Item 1. Legal Proceedings.~~Equity Method Investments

~~Currently we~~Investments accounted for using the equity method include those investments where the Company (i) can exercise significant influence over the other entity and (ii) holds common stock and/or in-substance common stock of the other entity. Under the equity method, investments are carried at cost, and subsequently adjusted for the Company’s share of net income (loss), comprehensive income (loss) and distributions received from the investee. If the current fair value of an investment falls below its carrying amount, this may indicate that an impairment loss should be recorded. Any impairment losses recognized are not ~~involved~~reversed in ~~any pending litigation or legal proceeding.~~subsequent periods. At February 28, 2022 and May 31, 2021, respectively, the Company has no equity method investments.

~~Item 1A. Risk Factors.~~Due from Related Party

WeFrom time to time, the Company may advance funds to an entity (IDP Macedonia) that is 50% controlled by our Former Chairman and Chief Executive Officer. While management believes the advances are expected to be recoverable, the recoverability of these advances depends on, amongst other things, Instadouz’s ability to generate positive cash flows through operations. In the event that Instadouz does not generate sufficient cash flows to support ongoing operations, the Company may be required to fund additional expenses. As a ~~smaller reporting company as defined by Rule 12b-2~~result of this and other uncertainties, the Company may ultimately not be able to recover some, or all, of the ~~Exchange Act~~value of these advances.

The IDP Macedonia collaboration is a revenue and ~~are~~expense sharing arrangement. Revenues generated from Instadouz’s sale of Medicinal Cannabis or Cannabinoid Oil is to be split 49% to the Company’s operating partner in the DRC (Instadouz DRC), 49% to the Company, and 2% to IDP Macedonia.

During the years ended May 31, 2021 and 2020, the Company has advanced IDP Macedonia a total of $929,313 and $150, respectively, of which all amounts were directly contributed by our Former Chairman and Chief Executive Officer, thereby, increasing loan payable – related party.

During the nine months ended February 28, 2022, the Company has advanced IDP Macedonia a total of $579,031, of which all amounts were directly contributed by our Chairman and Chief Executive Officer, thereby, increasing loan payable – related party.

Subsequent to February 28, 2022, the Company has not ~~required~~advanced any funds to ~~provide the information required under this item.~~IDP Macedonia. See Note 6.

~~Item 2. Unregistered Sales of Securities and Use of Proceeds.~~Joint Venture - Portugal

~~None~~

~~Item 3. Defaults Upon Senior Securities.~~

~~None~~

~~Item 4. Mining Safety Disclosures.~~

~~None~~

~~Item 5. Other Information.~~

On June 10, 2021, Instadose Pharma Corp. (the “Company”), filed with the Secretary of State of the State of Nevada an amendment to its articles of incorporation (the “Amendment”) to increase the authorized common stock from 500,000,000 shares to 700,000,000 shares, par value $.0001 per share, The Amendment also authorized the Company to issue up to 1,000,000 shares of blank check preferred stock, par value $.0001 per share.

In ~~consideration therefore, Executive will~~October 2020, the Company executed a joint venture in Portugal with a third party, which created an entity known as IDP Portugal. The purpose of this joint venture was to secure licenses to import Medicinal Cannabis into Portugal to be ~~paid a base salary of $8,000 per month. Said base salary shall not be decreased without his prior written consent. Executive will also receive a $600 car allowance (together with~~sold or processed into Cannabinoid Oil and then sold to pharmaceutical industry companies located predominantly in the ~~monthly salary, the “Base Salary”).~~European Union.

~~Upon termination by Executive~~Effective March 1, 2021, under the terms of ~~his employment for good reason or by the Company for any reason other than for “cause”, the Executive shall be entitled~~this arrangement, ownership of IDP Portugal is split 95% to his Base Salary through the end of the applicable term of the Agreement. Cause is defined in the Agreement as, among others, any act or omission that constitutes a material breach which is not cured following notice by the Company and 5% to the ~~willful and continued refusal of Executive to satisfactorily perform his duties, which failure continues after notice and the conviction of~~third party. IDP Portugal has not yet had any ~~felony or crime involving dishonesty.~~operations since its formation.

~~The Employment Agreement contains customary confidentiality provisions during and after~~During the ~~term of employment of Executive. Executive also agreed that during the term of his employment with~~year ended May 31, 2021, the Company advanced $29,106, all of which was directly contributed by our Chairman and ~~for one year thereafter he will~~Chief Executive Officer, thereby, increasing loan payable – related party.

During the nine months ended February 28, 2022, the Company did not ~~engage in~~advance any ~~business which competes with the business of the Company. The Company owes it’s CEO $43,000 in management fees for the period ended August 31, 2021~~funds to IDP Portugal.

Table of Contents

~~Item 6. Exhibits.~~INSTADOSE PHARMA CORP. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FEBRUARY 28, 2022

(UNAUDITED)

Joint Venture/Majority Owned Subsidiary - India

In January 2021, Instadose, along with its local partner in India, Sanctum Healthcare Remedies Private Limited (“Sanctum”), commenced official discussions with State government officials in Uttarakhand with a goal to secure a legal commercial license to grow, cultivate, process, and produce Medicinal Cannabis and Cannabinoid Oil (the “Uttarakhand License”) on agricultural lands located within the State of Uttarakhand (the “Uttarakhand Lands”).

In February 2021, Instadose and Sanctum agreed to a plan of joint venture that would see the parties work together in India to secure multiple State‑issued licenses to, among other rights, grow, cultivate, process, produce, export, and sell Medicinal Cannabis (according to India Law) and Cannabinoid Oil (the “India JV Licenses”) on certain agricultural lands in India (the “India JV Lands”) starting with the Uttarakhand License and Uttarakhand Lands (the “India Joint Venture”).

On February 18, 2021, Instadose and Sanctum executed a joint venture agreement (the “India JV Agreement”) formalizing their relationship under the India Joint Venture. In doing so, the India Joint Venture would serve the Global Distribution Platform as both a Medicinal Cannabis Cultivation Participant and Cannabinoid Oil Production Participant. The term of the India Joint Venture was agreed at twenty‑five (25) years, with a mutual option to extend the India Joint Venture for one additional twenty‑five (25) year term.

The India JV Agreement provided Instadose with exclusive rights to market and sell all of the Medicinal Cannabis and Cannabinoid Oil produced under the India Joint Venture with those net profits generated under the India Joint Venture to be shared as follows: Instadose 55%; Sanctum 45%.

On March18, 2021, Instadose and Sanctum incorporated a Subsidiary in India, Instadose Pharma India Private Limited (“IDP India”) to manage the India Joint Venture. IDP India is ownership is as follows: Instadose 55%; Sanctum 45%.

On August 6, 2021, the District Magistrate of Haridwar, in the State of Uttarakhand granted IDP India with its initial approval for the cultivation of Medicinal Cannabis, operating under the laws of India, on up to five hundred (500) acres of Uttarakhand Lands. IDP India is working to secure the Uttarakhand Lands. Once secured, approval to commence the official cultivation of Medicinal Cannabis in India (as well as receipt of the other applicable India JV Licenses) will be provided to IDP India.

During the nine months ended February 28, 2022 and the year ended May 31, 2021, the Company has advanced $0 and $775 to the joint venture.

Joint Venture – Mexico

In April 2021, Instadose and representatives of Instadose’s new third‑party partner in Mexico (the “Mexico Partner”) commenced discussions on a plan of joint venture/partnership that would see the parties work together in Mexico for the purposes of (i) growing, processing, purchasing, exporting, and selling Medicinal Cannabis, and (ii) utilizing Medicinal Cannabis to produce, export, and sell Cannabinoid Oil (collectively, the “Mexico Project”).

On July 29, 2021, Instadose and its Mexico Partner executed a letter agreement (the “Mexico Letter Agreement”) formalizing the scope of the Mexico Project which included the parties working together in Mexico.

During the nine months ended February 28, 2022 and the year ended May 31, 2021, there has been no activity with this joint venture.

~~31.1~~		~~Rule 13(a)-14(a)/15(d)-14(a) Certification of Chief Executive Officer~~

~~31.2~~		Rule 13(a)-14(a)/15(d)-14(a) Certification of Chief Financial Officer *

~~32.1~~		~~Section 1350 Certification of Chief Executive Officer~~

~~32.2~~		Section 1350 Certification of Chief Financial Officer **

~~101.INS~~		~~Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document).~~

~~101.SCH~~		~~Inline XBRL Taxonomy Extension Schema Document.~~

~~101.CAL~~		~~Inline XBRL Taxonomy Extension Calculation Linkbase Document.~~

~~101.DEF~~		~~Inline XBRL Taxonomy Extension Definition Linkbase Document.~~

~~101.LAB~~		~~Inline XBRL Taxonomy Extension Labels Linkbase Document.~~

~~101.PRE~~		~~Inline XBRL Taxonomy Extension Presentation Linkbase Document.~~

~~104~~		~~Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101).~~

* Included in Exhibit 31.1

** Included in Exhibit 32.1

Table of Contents

INSTADOSE PHARMA CORP. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FEBRUARY 28, 2022

(UNAUDITED)

Joint Venture – Colombia

In May 2021, Instadose and representatives of Instadose’s new third-party joint venture partner in Colombia (the “Colombia Partner”) commenced discussions on a plan of joint venture (the “Colombia Joint Venture”) that would see the Colombia Partner become an exclusive supplier to Instadose of no less than one million kilograms (1,000,000 kg) of Medicinal Cannabis per year throughout the term of the Colombia Joint Venture. The Colombia Partner is a Colombian company fully licensed in Colombia to cultivate and produce Medicinal Cannabis and its related derivatives.

On August 5, 2021, Instadose and its Colombia Partner executed a joint venture agreement (the “Colombia JV Agreement”) formalizing the scope of the Colombia Joint Venture. Under the Colombia JV Agreement, all of the Medicinal Cannabis to be supplied by the Colombia Partner to one or more Cannabinoid Oil Production Participants shall be determined in accordance with the terms of the supply agreements entered into between the applicable parties. Instadose and its Colombia Partner agreed to an initial five (5) year term for the operation of the Colombia Joint Venture subject to the right of the parties (absent the existence of a default) to extend the initial term for up to four (4) additional five (5) year terms.

During the nine months ended February 28, 2022 and the year ended May 31, 2021, there has been no activity with this joint venture.

Foreign Currency Translation

In preparing the financial statements of individual entities, transactions in currencies other than the entity’s functional currency are recognized at exchange rates in effect on the date of the transactions. At each reporting date monetary assets and liabilities denominated in foreign currencies are re-translated at the exchange rates applicable at that date. Non-monetary items carried at fair value that are denominated in foreign currencies are translated at the rates prevailing at the date when the fair value was determined. Non-monetary assets and liabilities that are measured at historical cost in a foreign currency are translated using the exchange rate at the date of the transaction. Realized and unrealized exchange gains and losses are recognized through net income (loss).

For the purposes of presenting consolidated financial statements the assets and liabilities of foreign operations, are translated into Canadian dollars at the exchange rates applicable at the balance sheet date. Income and expenses, and cash flows of foreign operations are translated into Canadian dollars using average exchange rates. Exchange differences resulting from translating foreign operations are recognized in accumulated other comprehensive income (loss). At February 28, 2022 and May 31, 2021, respectively, there were no accounts that required translation from a currency other than the Company’s functional currency (Canadian dollars).

Business Combinations

The Company accounts for business acquisitions using the acquisition method of accounting, in accordance with which assets acquired and liabilities assumed are recorded at their respective fair values at the acquisition date. The fair value of the consideration paid, including contingent consideration, is assigned to the assets acquired and liabilities assumed based on their respective fair values. Goodwill represents excess of the purchase price over the estimated fair values of the assets acquired and liabilities assumed.

Significant judgments are used in determining fair values of assets acquired and liabilities assumed, as well as intangibles. Fair value and useful life determinations are based on, among other factors, estimates of future expected cash flows, and appropriate discount rates used in computing present values. These judgments may materially impact the estimates used in allocating acquisition date fair values to assets acquired and liabilities assumed, as well as the Company’s current and future operating results. Actual results may vary from these estimates which may result in adjustments to goodwill and acquisition date fair values of assets and liabilities during a measurement period or upon a final determination of asset and liability fair values, whichever occurs first. Adjustments to fair values of assets and liabilities made after the end of the measurement period are recorded within the Company’s operating results.

Business Segments and Concentrations

The Company uses the “management approach” to identify its reportable segments. The management approach requires companies to report segment financial information consistent with information used by management for making operating decisions and assessing performance as the basis for identifying the Company’s reportable segments. The Company manages its business as one identifiable and reportable segment.

Table of Contents

INSTADOSE PHARMA CORP. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FEBRUARY 28, 2022

(UNAUDITED)

Fair Value of Financial Instruments

The Company accounts for financial instruments under Financial Accounting Standards Board (“FASB”) ASC 820, Fair Value Measurements. ASC 820 provides a framework for measuring fair value and requires disclosures regarding fair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, based on the Company’s principal or, in absence of a principal, most advantageous market for the specific asset or liability.

The Company uses a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to their initial measurement. The hierarchy requires the Company to use observable inputs when available, and to minimize the use of unobservable inputs, when determining fair value.

The three tiers are defined as follows:

	·	Level 1 —Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets;
	·	Level 2—Observable inputs other than quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities; and
	·	Level 3—Unobservable inputs that are supported by little or no market data, which require the Company to develop its own assumptions.

The determination of fair value and the assessment of a measurement’s placement within the hierarchy requires judgment. Level 3 valuations often involve a higher degree of judgment and complexity. Level 3 valuations may require the use of various cost, market, or income valuation methodologies applied to unobservable management estimates and assumptions. Management’s assumptions could vary depending on the asset or liability valued and the valuation method used. Such assumptions could include estimates of prices, earnings, costs, actions of market participants, market factors, or the weighting of various valuation methods. The Company may also engage external advisors to assist us in determining fair value, as appropriate.

Although the Company believes that the recorded fair value of our financial instruments is appropriate, these fair values may not be indicative of net realizable value or reflective of future fair values.

The Company’s financial instruments, including cash, and accounts payable and accrued expenses, are carried at historical cost. At February 28, 2022, and May 31, 2021, respectively, the carrying amounts of these instruments approximated their fair values because of the short-term nature of these instruments.

ASC 825-10 “Financial Instruments” allows entities to voluntarily choose to measure certain financial assets and liabilities at fair value (“fair value option”). The fair value option may be elected on an instrument-by-instrument basis and is irrevocable unless a new election date occurs. If the fair value option is elected for an instrument, unrealized gains and losses for that instrument should be reported in earnings at each subsequent reporting date. The Company did not elect to apply the fair value option to any outstanding financial instruments.

Cash and Cash Equivalents

For purposes of the consolidated statements of cash flows, the Company considers all highly liquid instruments with a maturity of three months or less at the purchase date and money market accounts to be cash equivalents. At February 28, 2022, and May 31, 2021, respectively, the Company did not have any cash equivalents.

Sales Tax Receivables

Sales taxes in Canada are imposed at two levels.

Table of Contents

INSTADOSE PHARMA CORP. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FEBRUARY 28, 2022

(UNAUDITED)

The federal government levies a national sales tax, the GST. Several provinces – British Columbia, Saskatchewan, Manitoba, Quebec, and Prince Edward Island – levy a separate retail sales tax often known as PST or combined to create the HST.

The GST is collected at a different rate when the related sale is made in Newfoundland and Labrador, Nova Scotia, New Brunswick, and Ontario. Tax collected at this rate is commonly referred to as the ‘harmonized sales tax’ or HST. It is important to note, however, that although the rates are different this tax is the same tax as the GST.

Impairment of Long-lived Assets

Management evaluates the recoverability of the Company’s identifiable intangible assets and other long-lived assets when events or circumstances indicate a potential impairment exists, in accordance with the provisions of ASC 360-10-35-15 “Impairment or Disposal of Long-Lived Assets.” Events and circumstances considered by the Company in determining whether the carrying value of identifiable intangible assets and other long-lived assets may not be recoverable include but are not limited to: significant changes in performance relative to expected operating results; significant changes in the use of the assets; significant negative industry or economic trends; and changes in the Company’s business strategy.

In determining if impairment exists, the Company estimates the undiscounted cash flows to be generated from the use and ultimate disposition of these assets.

If impairment is indicated based on a comparison of the assets’ carrying values and the undiscounted cash flows, the impairment to be recognized is measured as the amount by which the carrying amount of the assets exceeds the fair value of the assets.

Property and Equipment

Property and equipment is stated at cost less accumulated depreciation. Depreciation is provided on the straight-line basis over the estimated useful lives of the assets.

Expenditures for repair and maintenance which do not materially extend the useful lives of property and equipment are charged to operations. When property or equipment is sold or otherwise disposed of, the cost and related accumulated depreciation are removed from the respective accounts with the resulting gain or loss reflected in operations.

Management reviews the carrying value of its property and equipment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable.

For the nine months ended February 28, 2022, and 2021, respectively, the Company did not recognize any impairment loss.

At February 28, 2022, and May 31, 2021, respectively, none of the Company’s capitalized property, plant and equipment had been placed into service. Once operations begin, all assets will be depreciated over their estimated useful lives. See Note 4.

Right of Use Assets and Lease Obligations

The Right of Use Asset and Lease Liability reflect the present value of the Company’s estimated future minimum lease payments over the lease term, which may include options that are reasonably assured of being exercised, discounted using a collateralized incremental borrowing rate.

Typically, renewal options are considered reasonably assured of being exercised if the associated asset lives of the building or leasehold improvements exceed that of the initial lease term, and the performance of the business remains strong. Therefore, the Right of Use Asset and Lease Liability may include an assumption on renewal options that have not yet been exercised by the Company. At February 28, 2022, the Company’s operating lease did not contain any lease renewal options.

As the rate implicit in leases are not readily determinable, the Company uses an incremental borrowing rate to calculate the lease liability that represents an estimate of the interest rate the Company would incur to borrow on a collateralized basis over the term of a lease within a particular currency environment.

Table of Contents

INSTADOSE PHARMA CORP. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FEBRUARY 28, 2022

(UNAUDITED)

Intangible Rights – Related Party

Intangible assets consist of accessible license rights to cultivate Medicinal Cannabis in the DRC and is stated at cost less accumulated amortization. Amortization is provided for on the straight-line basis over the estimated useful life of the agreement which is twenty-five (25) years. See Notes 5 and 6.

Income Taxes

The Company accounts for income tax using the asset and liability method prescribed by ASC 740, “Income Taxes”. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date.

The Company follows the accounting guidance for uncertainty in income taxes using the provisions of ASC 740 ”Income Taxes”. Using that guidance, tax positions initially need to be recognized in the financial statements when it is more likely than not the position will be sustained upon examination by the tax authorities. As of May 31, 2021, and 2020, respectively, the Company had no uncertain tax positions that qualify for either recognition or disclosure in the financial statements.

The Company recognizes interest and penalties related to uncertain income tax positions in other expense. No interest and penalties related to uncertain income tax positions were recorded for the nine months ended February 28, 2022, and 2021, respectively.

As of February 28, 2022, all tax years remain open for audit.

Advertising Costs

Advertising costs are expensed as incurred. Advertising costs are included as a component of general and administrative expense in the consolidated statements of operations.

The Company recognized US$300,000 in marketing and advertising costs during the nine months ended February 28, 2022. The advertising costs were with respect to a media contract with Stellar Media entered into Instadose Pharma Corp. (USA) as previously disclosed in the 10-k filing on March 15, 2022.

Stock-Based Compensation

We account for our stock-based compensation under ASC 718 “Compensation – Stock Compensation” using the fair value-based method. Under this method, compensation cost is measured at the grant date based on the value of the award and is recognized over the service period, which is usually the vesting period. This guidance establishes standards for the accounting for transactions in which an entity exchanges it equity instruments for goods or services. It also addresses transactions in which an entity incurs liabilities in exchange for goods or services that are based on the fair value of the entity’s equity instruments or that may be settled by the issuance of those equity instruments.

We use the fair value method for equity instruments granted to non-employees and use the Black-Scholes model for measuring the fair value of options. The stock based fair value compensation is determined as of the date of the grant or the date at which the performance of the services is completed (measurement date) and is recognized over the vesting periods.

Table of Contents

INSTADOSE PHARMA CORP. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FEBRUARY 28, 2022

(UNAUDITED)

When determining fair value, the Company considers the following assumptions in the Black-Scholes model:

·	Exercise price,
·	Expected dividends,
·	Expected volatility,
·	Risk-free interest rate; and
·	Expected life of option

At February 28, 2022, and May 31, 2021, the Company had 3,000,000 and 0 options outstanding (subject to vesting), respectively.

SIGNATURES*Common Stock Awards

The Company may grant common stock awards to employees and consultants in exchange for services provided. The Company measures the fair value of these awards using the fair value of the services provided or the fair value of the awards granted, whichever is more reliably measurable. The fair value measurement date of these awards is generally the date the performance of services is complete. The fair value of the awards is recognized on a straight-line basis as services are rendered. The share-based payments related to common stock awards for the settlement of services provided by employees and consultants is recorded on the consolidated statement of operations in the same manner and charged to the same account as if such settlements had been made in cash.

Stock Warrants

In connection with certain financing, consulting and collaboration arrangements, the Company may issue warrants to purchase shares of its common stock. The outstanding warrants are standalone instruments that are not puttable or mandatorily redeemable by the holder and are classified as equity awards. The Company measures the fair value of the awards using the Black-Scholes option pricing model as of the measurement date. Warrants issued in conjunction with the issuance of common stock are initially recorded at fair value as a reduction in additional paid-in capital of the common stock issued. All other warrants are recorded at fair value as expense over the requisite service period or at the date of issuance if there is not a service period.

There were no warrant grants during the nine months ended February 28, 2022, and the year ended May 31, 2021, respectively.

Basic and Diluted Earnings (Loss) per Share

Pursuant to ASC 260-10-45, basic loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding for the periods presented. Diluted loss per share is computed by dividing net loss by the weighted average number of shares of common stock, common stock equivalents and potentially dilutive securities outstanding during the period. Potentially dilutive common shares may consist of common stock issuable for stock options and warrants (using the treasury stock method), convertible notes and common stock issuable. These common stock equivalents may be dilutive in the future.

During the nine months ended February 28, 2022, the Company granted 3,000,000 stock options (See Note 8). These options vest 1,000,000 each in June 2022 (fiscal year May 2023), June 2023 (fiscal year May 31, 2024) and June 2024 (fiscal year May 31, 2025). At February 28, 2022, none of these stock options had vested and were not exercisable, therefore, at February 28, 2022, there are no related common stock equivalents.

Table of Contents

INSTADOSE PHARMA CORP. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FEBRUARY 28, 2022

(UNAUDITED)

Related Parties

Parties are considered to be related to the Company if the parties, directly or indirectly, through one or more intermediaries, control, are controlled by, or are under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal with if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. See Notes 5 and 6 regarding the purchase of intangible rights and related loan payable with the Company’s Former Chairman and Chief Executive Officer.

Recent Accounting Standards

Changes to accounting principles are established by the FASB in the form of ASU’s to the FASB’s Codification. We consider the applicability and impact of all ASU’s on our financial position, results of operations, stockholders’ deficit, cash flows, or presentation thereof. Management has evaluated all recent accounting pronouncements as issued by the FASB in the form of Accounting Standards Updates (“ASU”) through the date these financial statements were available to be issued and found no recent accounting pronouncements issued, but not yet effective accounting pronouncements, when adopted, will have a material impact on the financial statements of the Company.

In September 2016, FASB issued ASU No. 2016-13, Measurement of Credit Losses on Financial Instruments, which supersedes current guidance by requiring recognition of credit losses when it is probable that a loss has been incurred.The new standard requires the establishment of an allowance for estimated credit losses on financial assets including trade and other receivables at each reporting date. The new standard will result in earlier recognition of allowances for losses on trade and other receivables and other contractual rights to receive cash. In November 2019, the FASB issued ASU No. 2019-10, Financial Instruments – Credit Losses (Topic 326), Derivatives and Hedging (Topic 815) and Leases (Topic 842), which extends the effective date of Topic 326 for certain companies until fiscal years beginning after December 15, 2022. The new standard will be effective for the Company in the first quarter of fiscal year June 1, 2023, and early adoption is permitted. The Company has not completed its review of the impact of this standard on its consolidated financial statements.

In December 2019, the FASB issued ASU 2019-12, “Simplifying the Accounting for Income Taxes.” This guidance, among other provisions, eliminates certain exceptions to existing guidance related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. This guidance also requires an entity to reflect the effect of an enacted change in tax laws or rates in its effective income tax rate in the first interim period that includes the enactment date of the new legislation, aligning the timing of recognition of the effects from enacted tax law changes on the effective income tax rate with the effects on deferred income tax assets and liabilities. Under existing guidance, an entity recognizes the effects of the enacted tax law change on the effective income tax rate in the period that includes the effective date of the tax law. ASU 2019-12 is effective for interim and annual periods beginning after December 15, 2020, with early adoption permitted. We adopted this pronouncement on March 1, 2021; however, the adoption of this standard did not have a material effect on the Company’s consolidated financial statements.

In June 2020, the FASB issued ASU No. 2020-06, Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40). This standard eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity’s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, the new guidance modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation. For public business entities, it is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years using the fully retrospective or modified retrospective method. Early adoption is permitted but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. We are currently evaluating the potential impact of this standard on our financial statements.

Table of Contents

INSTADOSE PHARMA CORP. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FEBRUARY 28, 2022

(UNAUDITED)

Note 3 – Disposal of Subsidiary – Related Party

On February 7, 2019, the Company disposed of its 100% owned subsidiary Maribec. The Company retained an irrevocable option to repurchase Maribec at a future time. On February 25, 2021, Maribec received its cannabis processing license. This license expires on September 4, 2023.

On March 11, 2021, the Company elected its option to repurchase Maribec, this transaction has not yet closed. The Company has determined that the reacquisition of Maribec is not subject to the business combination rules, rather this was deemed an asset purchase.

After the disposal of the subsidiary, during the nine months ended February 28, 2022, and the year ended May 31, 2021, the Company incurred additional expenses totaling $0 and $42,636, respectively. The advances were never repaid and resulted in a reduction to paid in capital.

Note 4 – Property, Plant and Equipment

The components of property, plant and equipment are as follows:

						Estimated Useful
	February 28, 2022		May 31, 2021			Lives (Years)

Buildings and improvements	$	1,187,979	$	1,050,648	*		39
Production and warehouse equipment		2,108,823		1,636,011	*		3 - 10
Land		466,984		466,984	*		N/A
Leasehold improvements		28,158		28,158	*		5
Furniture and fixtures		21,733		21,733	*		5
Hardware		18,200		18,200	*		5
Software		1,864		1,864	*		3
		3,833,741		3,223,598
Accumulated depreciation		0		0
Total property and equipment - net	$	3,833,741	$	3,223,598

* As of February 28, 2022 and May 31, 2021, none of the assets have been placed into service.

All of the Company’s property, plant and equipment will be placed into service upon commencement of operations, which is expected during the fiscal year ended May 2023.

Note 5 – Intangible Rights – Related Party

In October 2018, an affiliate of the Company’s Former Chairman and Chief Executive Officer, The Maye International Group SARL, (“TMIG”) entered into a business partnership with the DRC. On October 1, 2018, the DRC issued a registration certificate to TMIG for the cultivation of medicinal and food plants anywhere in the DRC for subsequent transformation into pharmaceutical products.

Under the terms of the agreement, TMIG committed $25,000,000 to the DRC to be used for the employment of agricultural professionals, building of infrastructure to grow and process cannabis, and to establish the exportation of product. The payment also allows the Company access to the Bukanga Lonzo Agro-Industrial Park to execute its operations, which primarily include the growing, transport, storing, processing, packaging and purchase of medicinal plants and medicinal plant derivatives for international export and sale.

The Company paid an additional $10,000,000 to TMIG to acquire the exclusive international rights to monetize the medicinal plant rights granted to TMIG by the DRC.

Total payments of $35,000,000 were made in USD and have been translated into Canadian dollars with a total valuation of $45,825,775.

The total payment of $45,825,775 to TMIG was paid directly from our Former Chairman and Chief Executive Officer during the period August 2018 to December 31, 2018. The Company effectively had acquired all rights associated with this agreement on January 1, 2019.

Table of Contents

INSTADOSE PHARMA CORP. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FEBRUARY 28, 2022

(UNAUDITED)

In the accompanying consolidated balance sheets, amounts paid by our Former Chairman and Chief Executive Officer on behalf of the Company were recorded as a loan payable, which is non-interest bearing, unsecured and due on demand. The loan was converted into 4,517,831 common shares on November 30 at a deemed price of Cdn$8.76 per common share. See Note 8.

The term of the agreement is for 25 years and, contingent upon the renewal of the DRC joint venture agreement with TMIG shall be renewable automatically for one additional twenty-five (25) year term. The Company has capitalized these intangible rights and will amortize the asset ratably over the term of the agreement.

The Company's intangible asset is as follows:

					Estimated Useful
	February 28, 2022		May 31, 2021		Life (Years)

Gross carrying amount	$	45,825,775	$	45,825,775		25
Accumulated amortization		5,804,598		4,429,825
Net carrying amount	$	40,021,177	$	41,395,950

Amortization expense for the nine months ended February 2022 and 2021 was $1,374,773 and $1,374,333, respectively.

See Note 6 regarding associated loan with related party.

Estimated amortization expense for each of the five (5) succeeding years and thereafter is as follows:

For the Year Ended May 31,

2022 (9 Months)	$	1,374,773
2023	$	1,833,031
2024	$	1,833,031
2025	$	1,833,031
Thereafter		33,147,311
Total	$	40,021,177

Table of Contents

INSTADOSE PHARMA CORP. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FEBRUARY 28, 2022

(UNAUDITED)

Note 6 – Loan Payable – Related Party

In connection with the Company acquiring rights to operate in the DRC, the Company’s Former Chairman and Chief Executive Officer paid all related amounts. See Note 5.

The following represents a summary of the Company’s loan payable – related party, key terms, and outstanding balances at February 28, 2022, and May 31, 2021, respectively:

	Loan Payable
Terms	Related Party

Issuance date of loan	Various
Term	Due on demand
Interest rate	0%
Collateral	Unsecured
Default	None

Balance - May 31, 2020	$	37,756,854
Proceeds		3,059,990
Repayments		(1,122,874	)
Balance - May 31, 2021		39,693,970
Advances		-
Repayments		(162,941	)
Debt Conversion		(39,531,029	)
Balance - February 28, 2022	$	-	*

* See 8 regarding debt conversion to common stock

The Company’s Current Interim Chairman and Interim Chief Executive Officer advanced $51,831 for the nine months ended February 28, 2022.

Note 7 – Commitments and Contingencies

Operating Lease

We have entered into an operating lease agreement for our corporate headquarters. We account for leases in accordance with ASC Topic 842: Leases, which requires a lessee to utilize the right-of-use model and to record a right-of-use asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases are classified as either financing or operating, with classification affecting the pattern of expense recognition in the statement of operations. In addition, a lessor is required to classify leases as either sales-type, financing or operating. A lease will be treated as a sale if it transfers all of the risks and rewards, as well as control of the underlying asset, to the lessee.

Table of Contents

INSTADOSE PHARMA CORP. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FEBRUARY 28, 2022

(UNAUDITED)

If risks and rewards are conveyed without the transfer of control, the lease is treated as financing. If the lessor does not convey risk and rewards or control, the lease is treated as operating. We determine if an arrangement is a lease, or contains a lease, at inception and record the lease in our financial statements upon lease commencement, which is the date when the underlying asset is made available for use by the lessor.

Right-of-use assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments over the lease term. Lease right-of-use assets and liabilities at commencement are initially measured at the present value of lease payments over the lease term. We generally use our incremental borrowing rate based on the information available at commencement to determine the present value of lease payments except when an implicit interest rate is readily determinable. We determine our incremental borrowing rate based on market sources including relevant industry data.

We have a lease agreement with lease and non-lease components and have elected to utilize the practical expedient to account for lease and non-lease components together as a single combined lease component, from both a lessee and lessor perspective with the exception of direct sales-type leases and production equipment classes embedded in supply agreements. From a lessor perspective, the timing and pattern of transfer are the same for the non-lease components and associated lease component and, the lease component, if accounted for separately, would be classified as an operating lease.

We have elected not to present short-term leases on the balance sheet as these leases have a lease term of 12 months or less at lease inception and do not contain purchase options or renewal terms that we are reasonably certain to exercise. All other lease assets and lease liabilities are recognized based on the present value of lease payments over the lease term at commencement date. Because most of our leases do not provide an implicit rate of return, we used our incremental borrowing rate based on the information available at lease commencement date in determining the present value of lease payments.

Our lease, where we are the lessee, does not include an option to extend the lease term. Our lease also includes an option to terminate the lease prior to the end of the agreed upon lease term. For purposes of calculating lease liabilities, lease term would include options to extend or terminate the lease when it is reasonably certain that we will exercise such options.

Lease expense for operating leases is recognized on a straight-line basis over the lease term as an operating expense, included as a component of general and administrative expenses, in the accompanying consolidated statements of operations.

Certain operating leases provide for annual increases to lease payments based on an index or rate, our lease has no stated increase, payments were fixed at lease inception. We calculate the present value of future lease payments based on the index or rate at the lease commencement date. Differences between the calculated lease payment and actual payment are expensed as incurred.

At February 28, 2022 and May 31, 2021, respectively, the Company has no financing leases as defined in ASC 842, "Leases."

Table of Contents

INSTADOSE PHARMA CORP. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FEBRUARY 28, 2022

(UNAUDITED)

The tables below present information regarding the Company's operating lease assets and liabilities at February 28, 2022 and May 31, 2021, respectively.

	February 28, 2022			May 31, 2021
Assets

Operating lease - right-of-use asset - non-current	$	161,719		$	242,579

Liabilities

Operating lease liability	$	186,005		$	270,141

Weighted-average remaining lease term (years)		1.75			2.50

Weighted-average discount rate		8	%		8	%

The components of lease expense were as follows:

Operating lease costs

Amortization of right-of-use operating lease asset	$	80,860		$	97,031
Lease liability expense in connection with obligation repayment		15,516		$	17,938
Total operating lease costs	$	96,376		$	114,969

Supplemental cash flow information related to operating leases was as follows:

Operating cash outflows from operating lease (obligation payment)	$	99,650		$	119,580
Right-of-use asset obtained in exchange for new operating lease liability	$	0		$	0

Future minimum lease payments required under leases that have initial or remaining non-cancelable lease terms in excess of one year at February 28, 2022:

2022 (3 Months)	$	29,895
2023		119,580
2024		59,790
Total undiscounted cash flows		209,265
Less: amount representing interest		(23,572	)
Present value of operating lease liability		185,693
Less: current portion of operating lease liability		(103,688	)
Long-term operating lease liability	$	82,005

Table of Contents

INSTADOSE PHARMA CORP. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FEBRUARY 28, 2022

(UNAUDITED)

Employment Agreements

The Company entered into several employment agreements with officers and directors, the terms were as follows:

	Accrued Compensation
Terms	Related Parties

Commencement date	February 8, 2019 - June 15, 2021
Term	3 years
End Date	February 8, 2022 - June 15, 2024
Salary	$150,000 - $350,000 per year

Balance - May 31, 2020	$	1,754,016
Expense incurred		1,383,334
Balance - May 31, 2021		3,137,350
Expense incurred		1,102,083
Balance - February 28, 2022	$	4,239,433

In addition to salary, certain officers and directors also received the right to accept additional shares of common stock as additional compensation. All of the shares granted vest ratably at the end of each anniversary over a period of three (3) years coinciding with the term of the related employment agreement.

In the event of a public listing of the Company, certain unvested common stock held by certain officers and directors become immediately vested. After the common stock is fully vested, the holder has 1 year from this date to take possession of the shares. On October 19, 2021, for certain employment agreements, and in anticipation of closing a reverse merger (recapitalization) and becoming listed on the OTC Market QB, the Company accelerated the vesting of an additional 9,500,000 shares having a fair value of $19,000,000, which were expensed and recognized in October 2021.

The Company has expensed these shares at each vesting date with a value based upon the fair value of the common stock on the vesting date.

For the nine months ended February 28, 2022, and 2020, the Company has recorded compensation expense related to these shares of $2,000,000 (1,000,000 shares) and $2,000,000 (1,000,000 shares), to an officer, respectively, based upon a recent third-party cash offering price of $2/share.

The stock grants vest as follows:

For the years ended May 31,	Cumulative Shares to be Vested

2022 (3 Months)		10,500,000	10,500,000
2023		1,000,000	11,500,000
2024		2,000,000	13,500,000
2025		2,000,000	15,500,000
		15,500,000

Of the 10,500,000 shares which vest in fiscal year end 2022, 9,500,000 relate to the acceleration of vesting for certain officers, directors, and consultants as noted above in relation to a public listing. The remaining 1,000,000 shares which vested related to compensation earned by the Company’s Chief Financial Officer (1,000,000 shares).

Table of Contents

INSTADOSE PHARMA CORP. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FEBRUARY 28, 2022

(UNAUDITED)

Note 8 – Stockholders’ Deficit

The Company has one class of common stock:

- Unlimited shares authorized

- No par value

- Voting at 1 vote per share

- Eligible for dividends if declared by the Board of Directors

Equity Transactions for the Nine Months February 28, 2022

Stock Issued for Services

The Company issued 14,962,409 shares of common stock for services rendered, having a fair value of $29,924,818 ($2/share), based upon recent third-party cash offerings. The Company expensed these services as a component of general and administrative expenses in the accompanying consolidated statements of operations.

Stock Issued for Services – Related Parties

The Company issued 1,900,000 shares of common stock for services rendered, having a fair value of $3,800,000 ($2/share), based upon recent third-party cash offerings. The Company expensed these services as a component of general and administrative expenses in the accompanying consolidated statements of operations.

Debt Conversion – Related Party

On October 19, 2021, the Company’s Former Chairman and Chief Executive Officer converted $39,531,029 of loan payable into 4,517,831 shares of common stock having a fair value of $9,035,662 ($2/share), based upon recent third-party cash offerings. The conversion resulted in a gain on debt settlement of $30,495,367. Since the transaction occurred with a related party, accordingly, the gain is recorded as an increase to additional paid in capital.

Plan of Arrangement

To account for the Plan of Arrangement that closed on December 31, 2021, the Company issued 190,940,653 shares to reflect the share conversion at 1.34 for every share held by Instadose Canada shareholders prior to the share exchange and to include the 75,001,200 shares outstanding in the public company prior to the share exchange. The issuance of shares was retroactively restated to reflect the recapitalization.

Stock Options

In June 2021, the Company executed a three (3) year consulting agreement with a service provider. The Company granted 3,000,000 stock options, having a fair value of $4,830,000. The options vest ratably at 1,000,000 per year at the end of year 1, 2 and 3, respectively. The options have an exercise price equal to $2. All options expire five (5) years from issuance in June 2026.

Fair value was based upon the following assumptions using a Black-Scholes option pricing model:

	Nine Months Ended
	February 28, 2022
Exercise Price	$	2.00
Expected Volatility		150	%
Expected Dividends		0	%
Expected Life in Years		3
Risk-free Interest rate		0.31	%

Table of Contents

INSTADOSE PHARMA CORP. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FEBRUARY 28, 2022

(UNAUDITED)

This consultant also received 1,500,000 shares of common stock having a fair value of $3,000,000 ($2/share), based upon recent third-party cash offerings. This amount was included in the above stock issued for services total.

Stock option transactions under the Company’s Plan for the three months ended February 28, 2022, and the year ended May 31, 2021, are summarized as follows:

					Weighted				Weighted
					Average				Average
			Weighted		Remaining		Aggregate		Grant
	Number of		Average		Contractual		Intrinsic		Date
Stock Options	Options		Exercise Price		Term (Years)		Value		Fair Value
Outstanding - May 31, 2021		-	$	-		-	$	-	$	-
Exercisable - May 31, 2021		-	$	-		-	$	-	$	-
Granted		3,000,000	$	2.00		4.25	$	-	$	1.61
Exercised		-	$	-		-	$	-	$	-
Cancelled Forfeited		-	$	-		-	$	-	$	-
Outstanding - February 28, 2022		3,000,000	$	2.00		4.25	$	-	$	-
Vested and Exercisable - February 28, 2022		-	$	-		-	$	-	$	-
Unvested and non-exercisable - February 28, 2022		3,000,000	$	2.00		4.25	$	-	$	-

Compensation expense recorded for stock-based compensation is as follows for the nine months ended February 28, 2022, and 2020, respectively:

As of February 28, 2022, compensation cost related to the unvested options not yet recognized was as follows:

3,622,500

Weighted average period in which unrecognized compensation will vest (in years)

2.25

The unvested stock option expense is expected to be recognized through June 2024.

Equity Transactions for the Year Ended May 31, 2021

Stock Issued for Services

The Company issued 6,723,423 shares of common stock for services rendered, having a fair value of $13,446,846 ($2/share), based upon recent third-party cash offerings. The Company expensed these services as a component of general and administrative expenses in the accompanying consolidated statements of operations.

Stock Issued for Services – Related Parties

The Company issued 7,772,856 shares of common stock for services rendered, having a fair value of $15,545,713 ($2/share), based upon recent third-party cash offerings. The Company expensed these services as a component of general and administrative expenses in the accompanying consolidated statements of operations.

Table of Contents

INSTADOSE PHARMA CORP. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FEBRUARY 28, 2022

(UNAUDITED)

Note 9 - Subsequent Events

Debt Settlement – Third Party (Accounts Payable)

In May 2019, the Company owed $485,690 to a third-party vendor. In November 2021, the Company executed a settlement with this vendor. Under the terms of the agreement, the Company is required to pay $845,000 in cash and 400,000 shares of common stock having a fair value of $800,000 ($2/share), based upon recent third-party cash offerings.

The amounts due in cash are payable as follows: $425,000 by December 31, 2021, and $420,000 by March 31, 2022. In the event that the total amount is not paid in full by March 31, 2022, an additional $100,000 becomes due and the outstanding balance will be subject to interest at 2% per month (annualized 24%). As at April 29, 2022, the Company had not paid the cash component of the settlement of $845,000.

In the accompanying balance sheet at May 31, 2021, the Company has included the $845,000 as a component of accounts payable and accrued expenses, and the $800,000 as common stock payable.

Additionally, the Company had previously issued 661,014 shares to this vendor in fiscal year 2020 which were accounted for as a deposit totaling $1,322,028. The Company and the vendor have agreed to treat this payment as a non-refundable deposit; however, no future purchases will be made by the Company. As a result, the Company has treated the impairment of this deposit as part of the aggregate settlement expense totaling $2,481,338.

The following is a summary of the settlement expense for the year ended May 31, 2021:

Total cash due upon settlement	$	845,000
Accounts payable - prior to settlement		(485,690	)
Additional cash owed		359,310
Common stock payable (400,000 shares)		800,000
Impairment of deposit		1,322,028
Settlement expense	$	2,481,338

Legal Matters

On December 30, 2021, Michael Deluca, a purported stockholder of the Company, filed a putative class action complaint in the U.S. District Court, Eastern District of Virginia, naming as defendants the Company and former CEO, Terry Wilshire. The complaint alleges violations of Section 10(b) of the Securities Exchange Act of 1934 (and SEC Rule 10b-5 promulgated thereunder), as well as a control person claim under Section 20(a) of the Exchange Act against Wilshire. The complaint alleges that defendants made materially false and misleading misrepresentations and omissions in SEC filings upon which plaintiff’s purportedly relied in purchasing shares of the Company and that plaintiff’s suffered harm when the price of the stock declined, and the purported truth emerged. Plaintiff seeks various forms of relief, including alleged damages, attorneys’ fees and costs and other relief. The Company intends to vigorously defend against this lawsuit, and at this time, the Company cannot predict the outcome or impact of the litigation.

On September 18, 2019, Instadose Canada received a letter from the Enforcement Branch of the Ontario Securities Commission, requesting information about Instadose Canada’s business activities. Instadose Canada is also aware that the OSC reached out to certain stakeholders of Instadose Canada regarding such enquiries. Instadose Canada has responded to these enquiries and has not received any response from the OSC since that time.

On July 9, 2021, the OSC announced that Grant F. Sanders had been charged quasi-criminally with one count of fraud. Mr. Sanders is charged in relation to his role as Chairman and Chief Executive Officer of Instadose Canada. The OSC alleges that investor funds were diverted to the benefit of Mr. Sanders, his family, and associates. The OSC further alleges that Instadose Canada materially misrepresented the nature of the company’s business. Mr. Sanders retained legal counsel in Canada for the purpose of vigorously defending himself against the Charge. Mr. Sanders’ first scheduled court appearance on this matter occurred on Monday, August 16, 2021. It was determined at the First Appearance that the matter be adjourned until 2022. For more information see the OSC’s press release at: https://www.newswire.ca/news-releases/ontario-securities-commission-osc-charges-grant-sanders-with-securities-act-offences-846017944.html

The Company may be involved in legal proceedings in the ordinary course of business. Such matters are subject to many uncertainties, and outcomes are not predictable with assurance.

Table of Contents

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

Forward-looking Statements

Statements in this Management’s Discussion and Analysis of Financial Condition and Results of Operation, as well as in certain other parts of this Annual report on Form 10-K (as well as information included in oral statements or other written statements made or to be made by the Company) that look forward in time, are forward-looking statements made pursuant to the safe harbor provisions of the Private Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, expectations, predictions, and assumptions and other statements that are other than statements of historical facts. Although the Company believes such forward-looking statements are reasonable, it can give no assurance that any forward-looking statements will prove to be correct. Such forward-looking statements are subject to, and are qualified by, known and unknown risks, uncertainties and other factors that could cause actual results, performance or achievements to differ materially from those expressed or implied by those statements. These risks, uncertainties and other factors include, but are not limited to the Company’s ability to estimate the impact of competition and of industry consolidation and risks, uncertainties and other factors set forth in the Company’s filings with the Securities and Exchange Commission, including without limitation to this Annual Report on Form 10-K.

The Company undertakes no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this Form 10-K.

Critical Accounting Policies

The Company’s financial statements and accompanying notes are prepared in accordance with accounting principles generally accepted in the United States of America. Preparing financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses. These estimates and assumptions are affected by management’s applications of accounting policies. Critical accounting policies for the Company include income taxes and recent accounting pronouncements.

The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America. All significant intercompany accounts and transactions have been eliminated in consolidation.

Income Taxes

The Company accounts for income tax using the asset and liability method prescribed by ASC 740, “Income Taxes”. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date.

The Company follows the accounting guidance for uncertainty in income taxes using the provisions of ASC 740 ”Income Taxes”. Using that guidance, tax positions initially need to be recognized in the financial statements when it is more likely than not the position will be sustained upon examination by the tax authorities. As of February 28, 2022, and 2021, respectively, the Company had no uncertain tax positions that qualify for either recognition or disclosure in the financial statements.

The Company recognizes interest and penalties related to uncertain income tax positions in other expense. No interest and penalties related to uncertain income tax positions were recorded for the years ended November 30, 2021, and 2020, respectively.

Table of Contents

In response to the COVID-19 pandemic, the Coronavirus Aid, Relief and Economic Security Act (“CARES Act”) was signed into law in March 2020. The CARES Act lifts certain deduction limitations originally imposed by the Tax Cuts and Jobs Act of 2017 (“2017 Tax Act”). Corporate taxpayers may carry back net operating losses (NOLs) originating between 2018 and 2020 for up to five years, which was not previously allowed under the 2017 Tax Act. The CARES Act also eliminates the 80% of taxable income limitations by allowing corporate entities to fully utilize NOL carry forwards to offset taxable income in 2018, 2019 or 2020. Taxpayers may generally deduct interest up to the sum of 50% of adjusted taxable income plus business interest income (30% limit under the 2017 Tax Act) for 2019 and 2020. The CARES Act allows taxpayers with alternative minimum tax credits to claim a refund in 2020 for the entire amount of the credits instead of recovering the credits through refunds over a period of years, as originally enacted by the 2017 Tax Act.

In addition, the CARES Act raises the corporate charitable deduction limit to 25% of taxable income and makes qualified improvement property generally eligible for 15-year cost- recovery and 100% bonus depreciation. The enactment of the CARES Act did not result in any material adjustments to our income tax provision for the years ended February 28, 2022, and 2021, respectively.

Recent Accounting Pronouncements

Trends and Uncertainties

The Company currently has minimal revenues and operations and is investigating potential businesses and companies for acquisition to create and/or acquire a sustainable business. Our ability to acquire or create a sustainable business may be adversely affected by our current financial conditions, availability of capital and/ or loans, general economic conditions which can be cyclical in nature along with prolonged recessionary periods, and other economic and political situations.

The Company has generated recurring losses and cash flow deficits from its operations since inception and has had to continually borrow to continue operations. These matters raise substantial doubt about the Company’s ability to continue as a going concern. The continued operations of the Company are dependent upon its ability to raise additional capital, obtain additional financing and/or generate positive cash flows from operations. As further described in “Liquidity and Capital Resources”, management believes that it will be successful in obtaining additional financing, from which the proceeds will be primarily used to execute its new operating plans. The Company plans to use its available cash and new financing to develop and execute its new business plan and hopefully create and maintain a self-sustaining business. However, the Company can give no assurances that it will be successful in achieving its plans or if financing will be available or, if available, on terms acceptable to the Company, or at all. Should the Company not be successful in obtaining the necessary financing to fund its operations, and ultimately achieve adequate profitability and cash flows from operations, the Company would need to curtail certain or all of its operating activities.

There are no trends, events or uncertainties that have had or are reasonably expected to have a material impact on the net sales or revenues or income from continuing operations. There are no significant elements of income or loss that do not arise from our continuing operations except for the fair value change on derivative financial instruments and settlement on arbitration.

The rapid advances in computing and telecommunications technology over the past several decades have brought with them increasingly sophisticated methods of delivering administrating elections. Along with these advances, though, have come risks regarding the integrity and privacy of data, and these risks apply to election companies, falling into the general classification of cybersecurity. While it is not possible for anyone to give an absolute guarantee that data will not be compromised, when applicable, the Company shall utilize third-party service providers to secure the Company’s financial and personal data; the Company believes that third-party service providers provide reasonable assurance that the financial and personal data that they hold are secure.

Table of Contents

Liquidity and Capital Resources

As of February 28, 2022, the Company had an accumulated deficit of $(172,724,015) and a working capital deficit of $(10,087,817). Our ability to continue as a going concern depends upon whether we can ultimately attain profitable operations, generate sufficient cash flow to meet our obligations, and obtain additional financing as needed.

As of May 31, 2021, the Company had an accumulated deficit of $(134,913,341) and a working capital deficit of $45,896,979.

Operating Activities

For the nine months ended February 28, 2022, the Company recorded a net loss of $(37,810,674). We had stock issued for services of $29,924,818, stock issued for services to related parties of $3,800,000, accrued salaries of $1,134,083, amortization of intangible assets of $1,374,768 and other expenses of $1,577,005. As a result, we recorded net cash used in operating activities of $1,504,372 for the nine months ended February 28, 2022.

For the nine months ended February 28, 2021, the Company recorded a net loss of $(20,580,874). We had stock issued for services of $9,692,559, stock issued for services to related parties of $8,000,000, accrued salaries of $1,058,833, amortization of intangible assets of $1,374,768 and other expenses of $(889,366). As a result, we recorded net cash used in operating activities of $(434,652) for the nine months ended February 28, 20220

Investing Activities

For the nine months ended February 28, 2022, we had advances from related parties of $803,189, advances to joint venture partners of $63,490 and purchases of equipment for $472,812. As a result, we recorded net cash used in investing activities of $1,339,491 for the nine months ended February 28, 2022.

For the nine months ended February 28, 2021, we had advances from related parties of $296,867. As a result, we recorded net cash used in investing activities of $296,867 for the nine months ended February 28, 2022.

Financing Activities

For the nine months ended February 28, 2022, we had advances on a loan payable from a related party of $51,831, repayments on a loan payable to a related party of $137,332 and we had debt from a related party converted to equity of $39,585,310.

For the nine months ended February 28, 2022, we received related party advances of $797,403.

Management believes that it will be able to continue its operations and further advance its business plans. However, management cannot give assurances that such plans will materialize and be successful in the near term or on terms advantageous to the Company, or at all. Should the Company not be successful in its business plans or obtain additional financing, the Company would need to curtail certain or all of its operating activities.

The Company’s continuation as a going concern is dependent upon its ability to ultimately attain profitable operations, generate sufficient cash flow to meet its obligations, and obtain additional financing as may be required. For the nine months ended May 31, 2021, and 2020, our auditors have included a “going concern” modification in their auditors’ reports. A “going concern” modification may make it more difficult for us to raise funds when needed. The outcome of this uncertainty cannot presently be determined.

The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty. There can be no assurance that management will be successful in implementing its business plan or that the successful implementation of such business plan will actually improve our operating results

Results of Operations for the Nine Months Ended February28, 2022 Compared to the Nine Months Ended February 28, 2021

The Company did not earn any revenues for the nine months ended February 28, 2022, or 2021.

Table of Contents

General and administrative expenses for the nine months ended February 28, 2022, totaled $36,395,938 compared to $19,266,106 for the nine months ended February 28, 2021, an increase of $17,129,832.

General and administrative expenses for the nine months ended February 28, 20221 consisted primarily of stock issued for services of $29,924,818, stock issued for services to related parties of $3,800,000, accrued salaries of $1,134,083, amortization of intangible assets of $1,374,768 and other expenses of $1,577,005. Stock issued for services increased $20,232,259 and stock issued for services to related parties decreased by $4,200,000 as compared to the nine-month period ended February 28, 2021.

Off-Balance Sheet Arrangements

We do not maintain any off-balance sheet arrangements, transactions, obligations or other relationships with unconsolidated entities that would be expected to have a material current or future effect upon our financial condition or results of operations.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not applicable

ITEM 4. CONTROLS AND PROCEDURES

Controls and Procedures

During the nine months ended February 28, 2022, there were no changes in our internal controls over financial reporting (as defined in Rule 13a-15(f) and 15d-15(f) under the Exchange Act) that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Evaluation of Disclosure Controls and Procedures

Under the supervision and with the participation of our management, including our chief executive officer and principal financial officer, we conducted an evaluation of our disclosure controls and procedures, as such term is defined under Rule 13a-15(e) and Rule 15d-15(e) promulgated under the Securities Exchange Act of 1934, as amended, as of February 28, 2022. Based on this evaluation, our chief executive officer and principal financial officers have concluded such controls and procedures were not effective as of February 28, 2022 to ensure that information required to be disclosed by the issuer in the reports that it files or submits under the Act is recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and forms and to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Act is accumulated and communicated to the issuer’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the company’s annual or interim financial statements will not be prevented or detected on a timely basis. In the course of making our assessment of the effectiveness of internal controls over financial reporting, we identified material weaknesses in our internal control over financial reporting as follows.

	·	The relatively small number of employees who are responsible for accounting functions prevents us from segregating duties within our internal control system.
	·	Our internal financial staff lack expertise in identifying and addressing complex accounting issued under U.S. Generally Accepted Accounting Principles.

Upon receiving adequate financing, the Company plans to increase its controls in these areas by hiring more employees in financial reporting and establishing an audit committee.

A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. The design of any system of controls is also based in part on certain assumptions regarding the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Given these and other inherent limitations of control systems, there is only reasonable assurance that our controls will succeed in achieving their stated goals under all potential future conditions.

Important Considerations

The effectiveness of our disclosure controls and procedures and our internal control over financial reporting is subject to various inherent limitations, including cost limitations, judgments used in decision making, assumptions about the likelihood of future events, the soundness of our systems, the possibility of human error, and the risk of fraud. Moreover, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions and the risk that the degree of compliance with policies or procedures may deteriorate over time. Because of these limitations, there can be no assurance that any system of

disclosure controls and procedures or internal control over financial reporting will be successful in preventing all errors or fraud or in making all material information known in a timely manner to the appropriate levels of management.

Table of Contents

PART II

ITEM 1. LEGAL PROCEEDINGS

The Company may be involved in legal proceedings in the ordinary course of business. Such matters are subject to many uncertainties, and outcomes are not predictable with assurance.

ITEM 1A. RISK FACTORS

The following is a summary of certain risk factors relating to the activities of the Company and its subsidiaries and the ownership of the Company’s securities. The risks and uncertainties described below are those the Company currently believe to be material, but they are not the only ones the Company faces.

Table of Contents

Risks Generally Related to the Company

1. Market Risks for Securities

Volatility in the price of the Company’s shares could cause our shareholders to lose all or part of their investment because they may not be able to our shares at or above the price they paid. Factors that could cause fluctuations in the market price of our shares include the following:

	·	price and volume fluctuations in the overall stock market from time to time:
	·	volatility in the market prices and trading volumes of stocks of companies that are involved in the same industry as the Company;
	·	changes in operating performance and stock market valuations of other companies that are involved in the same industry as the Company;
	·	sales of our shares by our shareholders;
	·	announcements by our competitors regarding new products or services;
	·	the public’s reaction to our news releases, other public announcements, and filings with securities commissions;
	·	rumors and market speculation involving the Company or other companies in our industry;
	·	actual or anticipated changes in our operating results or fluctuations in our operating results;
	·	actual or anticipated developments in our business, or that of its competitors or the competitive landscape generally;
	·	litigation involving the Company, its industry or both, or investigations by regulatory into our operations or those of its competitors;
	·	developments or disputes concerning our intellectual property or other proprietary rights;
	·	announced or completed acquisitions of businesses or technologies by the Company or its competitors;
	·	new laws or regulations or new interpretations of existing laws or regulations applicable to our business;
	·	changes in accounting standards, policies, guidelines, interpretations, or principles;
	·	any significant changes in our management; and
	·	general economic conditions and slow or negative growth of the Company’s markets.

2. The Company is a development stage company, and we cannot assure profitability

Our lack of operating history makes it difficult for investors to evaluate our prospects for success. Prospective investors should consider the risks and difficulties we might encounter, since there is no assurance that it will be successful. Any likelihood of success must be considered considering our relative early stage of operations.

As we have only just begun to generate revenue, it is extremely difficult to make accurate predictions and forecasts of our finances. There is no guarantee that our products or services will be attractive to potential consumers.

3. Our actual financial position and results of operations may differ materially from the expectations of management

Our actual financial position and results of operations may differ materially from management’s expectations. As a result, the Company’s revenue, net income and cash flow may differ materially from the Company’s projected revenue, net income, and cash flow. The process for estimating the Company’s revenue, net income and cash flow requires the use of judgment in determining the appropriate assumptions and estimates. These estimates and assumptions may be revised as additional information becomes available and as additional analyses are performed. In addition, the assumptions used in planning may not prove to be accurate, and other factors may affect The Company’s financial condition or results of operations.

Table of Contents

4. There is no assurance that the Company will turn a profit or pay dividends

The Company has limited history of earnings, limited cash reserves, a limited operating history, has not paid dividends, and is unlikely to pay dividends in the immediate or near future. The Company has a history of operating losses and may not achieve or sustain profitability. The Company cannot guarantee shareholders that it will become profitable, and even if the Company achieves profitability, given the competitive and evolving nature of the industry in which it operates, the Company may not be able to sustain or increase profitability and its failure to do so could adversely affect the Company’s business, including its ability to raise additional funds.

There can be no assurance that the Company will be profitable or pay dividends. The payment and amount of any future dividends will depend on, among other things, the Company’s results of operations, cash flow, financial condition, and operating and capital requirements. There is no assurance that future dividends will be paid, and, if dividends are paid, there is no assurance with respect to the amount of any such dividends.

5. There are factors which may prevent the Company from the realization of growth targets

The Company is currently expanding from its early development stage. The Company’s growth strategy contemplates continuing development of its Global Distribution Platform and the Industry Gateway. There is a risk that the development of these platforms will not be achieved on time, on budget, or at all, as they can be adversely affected by a variety of factors, including some that are discussed elsewhere in these “Risk Factors” and the following:

	·	non‑performance by third party contractors;
	·	increases in materials or labor costs;
	·	falling below expected levels of output or efficiency;
	·	labor disputes, disruptions or declines in productivity;
	·	termination or non‑renewal of long‑term contracts; and
	·	inability to attract enough qualified workers.

6. Risk of Additional Financing

The Company is in the development stage and have not generated a significant amount of revenue. The Company will likely operate at a loss until business becomes established and it may require additional financing to fund future operations and expansion plans, including developing new products, enhancing existing products, enhancing its operating infrastructure, and acquiring complementary businesses and technologies. The Company’s ability to secure any required financing to sustain operations will depend in part upon prevailing capital market conditions, as well as business success. There can be no assurance that the Company will be successful in its efforts to secure any additional financing or additional financing on terms satisfactory to management. If additional financing is raised by issuing the Company shares in its authorized capital, control may change, and shareholders may suffer additional dilution.

7. Going‑Concern Risk

The Company’s financial statements have been prepared on a going concern basis under which an entity is able to realize its assets and satisfy its liabilities in the ordinary course of business. The Company’s future operations are dependent upon the identification and successful completion of equity or debt financing and the achievement of profitable operations at an indeterminate time in the future. There can be no assurances that the Company will be successful in completing equity or debt financing or in achieving profitability. The financial statements do not give effect to any adjustments relating to the carrying values and classification of assets and liabilities that would be necessary should the Company be unable to continue as a going concern.

Table of Contents

8. Competition

The Company faces competition in the markets in which it operates and intends to operate soon. Some of the Company’s competitors may be better positioned to develop superior product features and technological innovations, and able to better adapt to changing market conditions. The Company’s ability to compete depends on, among other things, consistent high product quality, short lead time, timely delivery, competitive pricing, range of product offerings and superior customer service and support. Increased competition in the markets in which the Company operates may force the Company to reduce its product prices or may result in increased costs and may have a material adverse effect on its business and operating results. Any decrease in the quality of the Company’s products or level of service to customers, or any forced decrease in product pricing may adversely affect its business and operating results.

In addition, the industry in which the Company operates is highly competitive. the Company may not have sufficient resources to maintain any competitive advantages, including research and development, marketing, sales, and customer services on a competitive basis which could materially and adversely affect the Company’s business, financial condition, and results of operations.

9. Agricultural Operations Risk

The Company’s business is dependent on the growth and production of cannabis products, an agricultural product. As such, the risks inherent in engaging in agricultural businesses apply to the Company. Potential risks include the risk that crops may become diseased or victim to insects or other pests and contamination, or subject to extreme weather conditions such as excess rainfall, freezing temperature, or drought, all of which could result in low crop yields, decreased availability of cannabis, and higher acquisition prices. Although the Company has taken on a strategy to source its cannabis from various geographical locations, there can be no guarantee that an agricultural event will not adversely affect the Company’s business and operating results. Furthermore, the impact of Global Warming and other environmental effects on weather systems around the globe may impact the agricultural businesses upon which the Company relies.

10. Success of Quality Control Systems

The quality and safety of the Company’s products are critical to the success of its business and operations. As such, it is imperative that the Company’s and its service providers’ quality control systems operate effectively and successfully. Quality control systems can be negatively impacted by the design of the quality control systems, the quality training program, and adherence by employees to quality control guidelines. Although the Company strives to ensure that all its service providers have implemented and adhere to high‑caliber quality control systems, any significant failure or deterioration of such quality control systems could have a material adverse effect on the Company’s business and operating results.

11. Reliance on Third Party Suppliers and Manufacturers

The Company intends to maintain a full supply chain to produce wholesale bulk cannabis. The Company’s co‑packers and ingredient and packaging suppliers may elect, at any time, to cease to engage in production agreements for products containing cannabis. Loss of manufacturers and suppliers would have a material adverse effect on the Company’s business and operational results.

12. Product Liability

The Company’s products are produced for sale both directly and indirectly to end consumers, and therefore the Company faces an inherent risk of exposure to product liability claims, regulatory action, and litigation of the Company’s products alleging to have caused significant loss or injury. In addition, the manufacture and sale of cannabis and cannabis related products involves the risk of injury to consumers due to tampering by unauthorized third parties or product contamination. Previously unknown adverse reactions resulting from human consumption of the Company’s products alone or in combination with other medications or substances could occur. The Company may be subject to various product liability claims, including, among others, that its products caused injury or illness, include inadequate instructions for use or include inadequate warnings concerning possible side effects or interactions with other substances. A product liability claims or regulatory action against the Company could result in increased costs, could adversely affect the Company’s reputation, and could have a material adverse effect on the Company’s business and operational results.

Table of Contents

13. Product Recalls

Product manufacturers and distributors are sometimes required to recall or initiate returns of their products for various reasons, including product defects such as contaminations, unintended harmful side effects or interactions with other products, packaging safety and inadequate or inaccurate labeling disclosure. If any of the Company’s products are recalled, the Company could incur unexpected expense relating to the recall and any legal proceedings that might arise in connection with the recall. the Company may lose significant revenue due to loss of sales and may not be able to compensate for or replace that revenue. A recall of the Company’s products could lead to adverse publicity, decreased demand for the Company’s products and could have a material adverse effect on the Company’s results of operations and financial condition.

14. Maintaining and Promoting the Company’s Brand

The Company believes that maintaining and promoting its brand is critical to expanding its customer base. Maintaining and promoting the Company’s brand will depend largely on its ability to continue to provide quality, reliable, sustainable, and innovative products, which the Company may not do successfully. Maintaining and enhancing the Company’s brand may require it to make substantial investments, and these investments may not achieve the desired goals. If the Company fails to successfully promote and maintain its brand or if it incurs excessive expenses in this effort, the Company’s business and financial results from operations could be materially adversely affected.

15. Key Personnel Risk

The Company’s success and future growth will depend, to a significant degree, on the continued efforts of the Company’s directors and officers to develop the business and manage operations and on their ability to attract and retain key technical, scientific, sales and marketing staff or consultants. The loss of any key person or the inability to attract and retain new key persons could have a material adverse effect on the Company’s business. Competition for qualified technical, scientific, sales and marketing staff, as well as officers and directors can be intense, and no assurance can be provided that the Company will be able to attract or retain key personnel in the future. The Company’s inability to retain and attract the necessary personnel could materially adversely affect the Company’s business and financial results from operations.

16. Fluctuations in Foreign Currency Exchange Rates

The Company is subject to foreign currency risk. The strengthening or weakening of the Canadian or US dollar versus other currencies of other countries in which it operates, will impact the translation of the Company’s net revenues generated in these foreign currencies into Canadian and US dollars. The Company imports certain ingredients in its products from foreign countries, and so may become forced to pay higher rates for the Company’s ingredients because of the weakening of the Canadian or US dollar.

17. Risks Related to the Company’s Prices

As the market for the Company’s products matures, or as new or existing competitors introduce new products or services that compete with ours, the Company may experience pricing pressure and be unable to renew its agreements with existing customers or attract new customers at prices that are consistent with the Company’s pricing model and operating budget. If this were to occur, it is possible that the Company would have to change its pricing model or reduce the Company’s prices, which could harm the Company’s revenue, gross margin, and operating results.

18. Requirement to Generate Cash Flow for Financial Obligations

The Company currently has negative operating cash flows. The Company’s ability to generate sufficient cash flow from operations to make scheduled payments to its contractors, service providers and suppliers will depend on future financial performance, which will be affected by a range of economic, competitive, regulatory, legislative, and business factors, many of which are outside of the Company’s control. If the Company does not generate sufficient cash flow from operations to satisfy its contractual obligations, the Company may have to undertake alternative financing plans. The Company’s inability to generate sufficient cash flow from operations or undertake alternative financing plans would have an adverse effect on the Company’s business, financial condition and results or operations, as well as its ability to satisfy the Company’s contractual obligations. Any failure to meet the Company’s financial obligations could result in termination of key contracts, which could harm the Company’s ability to provide its products.

Table of Contents

19. Uninsured or Uninsurable Risk

The Company may become subject to liability for risks which are uninsurable or against which the Company may opt out of insuring due to the high cost of insurance premiums or other factors. The payment of any such liabilities would reduce the funds available for usual business activities. Payment of liabilities for which insurance is not carried may have a material adverse effect on the Company’s financial position and operations.

20. Conflicts of Interest Risk

Certain of the Company’s directors and officers are, and may continue to be, involved in other business ventures in cannabis or hemp products and the nutraceutical industry through their direct and indirect participation in corporations, partnerships, joint ventures, etc. that may become potential competitors to the Company. Situations may arise in connection with potential acquisitions or opportunities where the other interests of these directors’ and officers’ conflict with or diverge from the Company’s interests. In accordance with the BCBCA, directors who have a material interest in any person who is a party to a material contract, or a proposed material contract are required, subject to certain exceptions, to disclose that interest and generally abstain from voting on any resolution to approve the contract. In addition, the directors and officers are required to act honestly and in good faith with a view to the Company’s best interests. However, in conflict‑of‑interest situations, directors and officers may owe the same duty to another company and will need to balance their competing interests with their duties to the Company. Circumstances (including with respect to future corporate opportunities) may arise that may be resolved in a manner that is unfavorable to the Company.

21. Infectious Diseases and Global Virus Outbreaks

Emerging infectious diseases or the threat of outbreaks of viruses or other contagions or epidemic diseases, including the Covid‑19 outbreak, could have a material adverse effect on the Company by causing operational delays and disruptions (including as a result of government regulation and prevention measures), labor shortages and shutdowns, social unrest, breach of material contracts, government or regulatory actions or inactions, changes in tax laws, payment deferrals, increased insurance premiums, governmental disruptions, capital markets volatility, or other unknown but potentially significant responses or consequences. In addition, governments may impose strict emergency measures in response to the threat or existence of an infectious disease. The full extent and impact of the Covid‑19 pandemic is unknown and, to‑date, has included volatility in financial markets, a slowdown in economic activity and has also raised the prospect of a global recession.

The international response to Covid‑19 has led to significant restrictions on travel, temporary business closures, quarantines, global stock market volatility and a general reduction in consumer activity. At this time, the Company cannot accurately predict what effects these conditions will have on its financial position and results of operations, including due to uncertainties relating to the ultimate geographic spread of the virus, the severity of the disease, the duration of the outbreak, and the length of the travel restrictions and business closures that have been or may be imposed by the governments of impacted regions. In addition, a significant outbreak of contagious diseases in the human population, such as Covid‑19, could result in a widespread health crisis that could adversely affect the economies and financial markets of many countries, resulting in an economic downturn that could result in a material adverse effect on demand for financial compliance services, investor confidence, and general financial market liquidity, all of which may adversely affect the Company’s business and the fair market value of the Company shares. Accordingly, any outbreak or threat of an outbreak of an epidemic disease or similar public health emergency, including Covid‑19, could have a material adverse effect on the Company’s business, financial condition, and results of operations. As at the date hereof, the duration of any business disruptions and related financial impact of the Covid‑19 outbreak cannot be reasonably estimated. It is unknown whether and how the Company may be affected if a pandemic, such as the Covid‑19 outbreak, persists for an extended period.

Table of Contents

22. The Company May Become Subject to Litigation

In addition to the current class action lawsuit, the Company may be named as a defendant in a lawsuit or regulatory action. the Company may also incur uninsured losses for liabilities which arise in the ordinary course of business, or which are unforeseen, including, but not limited to, employment liability and business loss claims. Any such losses could have a material adverse effect on the Company’s business, results of operations, sales, cash flow or financial condition.

Regulatory Risks

23. Regulatory Approvals and Permits

The activities of the Company are subject to regulation by governmental authorities of jurisdictions in which it or its partners operate. Achievement of the Company’s business objectives is contingent, in part, upon compliance with regulatory requirements enacted by these governmental authorities and obtaining all regulatory approvals, where necessary, for the import, export and sale of its products. the Company may be required to obtain and maintain certain permits, licenses, and approvals in the jurisdictions where the Company’s products are licensed, although it does not currently anticipate that such approvals will be necessary. There can be no assurance that the Company will be able to obtain or maintain any necessary licenses, permits or approvals, and any material delay or inability to receive these items is likely to delay and/or inhibit the Company’s ability to conduct its business, and would have an adverse effect on the Company’s business, financial condition, and results of operations.

24. Potential Changes in Federal and State Laws and Regulations

If state and/or federal legislation changes or regulatory agencies amend their practices or interpretive policies, or expended its resources enforcing existing state and/or federal laws, such action(s) could have a materially adverse effect on; (a) the Company’s ability to obtain lawfully sourced raw materials; and (b) the manufacturing, marketing, distribution, and sale of the Company’s products in one or multiple jurisdictions, up to and including a complete interruption of its business. Further, additional government disruption in the cannabis industry could cause potential customers and users to be reluctant to purchase the Company’s products, which would be detrimental. The Company cannot predict the nature of any future federal, state and/or laws, regulations, interpretations, or applications, nor can it determine what effect additional governmental regulations or administrative policies and procedures, when and if promulgated, could have on its business.

Intellectual Property Risks

25. Risks Related to Potential Inability to Protect Intellectual Property

The Company’s success is heavily dependent upon its intellectual property and technology. The Company licenses certain technology from third parties and there can be no assurance that it will be able to continue licensing these rights on a continuous basis. The Company relies upon copyrights, trade secrets, unpatented proprietary know‑how and continuing technology innovation to protect the technology that it considers important to the development of its business. The Company relies on various methods to protect its proprietary rights, including confidentiality agreements with its consultants, service providers and management that contain terms and conditions prohibiting unauthorized use and disclosure of its confidential information. However, despite the Company’s efforts to protect its intellectual property rights, unauthorized parties may attempt to copy or replicate its technology. There can be no assurances that the steps taken by the Company to protect its technology will be adequate to prevent misappropriation or independent third‑party development of its technology. It is likely that other companies can duplicate a production process like ours. To the extent that any of the above could occur, the Company’s revenue could be negatively affected, and in the future, the Company may have to litigate to enforce its intellectual property rights, which could result in substantial costs and divert management’s attention and its resources.

Table of Contents

Economic Risks

26. Global Economy Risk

The current Covid‑19 pandemic and, prior to that, the economic slowdown and downturn of global capital markets has generally made the raising of capital by equity or debt financing more difficult. If the Arrangement is not completed, the Company will be dependent upon the capital markets to raise additional financing in the future. Access to financing has been negatively impacted by the ongoing global economic downturn. As such, the Company is subject to liquidity risks in meeting development and future operating cost requirements in instances where cash positions are unable to be maintained or appropriate financing is unavailable. These factors may impact the Company’s ability to raise equity or obtain loans and other credit facilities in the future and on terms favorable to it and management. If uncertain market conditions persist, the ability to raise capital could be jeopardized and thus have an adverse impact on operations and on the trading price of the Company’s shares on OTC Pink (assuming the completion of the Arrangement).

27. Trends, Risks and Uncertainties

The Company has sought to identify what it believes to be the most significant risks to its business, but it cannot predict whether, or to what extent, any of such risks may be realized nor can it guarantee that it has identified all possible risks that might arise. Investors should carefully consider all such risk factors before making an investment decision with respect to the Company shares.

Regulatory Risks and Uncertainties

28. Trading Suspension and Caveat Emptor

The recent SEC trading suspension and the designation of Caveat Emptor on the OTC Markets has negatively affected the ability of the Company’s shareholders to trade their shares. Although the Company is currently taking steps to rectify the regulatory restrictions, there is no guarantee that they will be successful in a timely manner.

29. Ontario Securities Commission’s charges against former officer and director of the Company and Instadose Canada will continue to have a negative effect on the ability of the Company to create an active market and successfully implement its business plan.

On July 9, 2021, the Ontario Securities Commission announced that Grant F. Sanders had been charged quasi-criminally with one count of fraud. Mr. Sanders is charged in relation to his role as Chairman and Chief Executive Officer of Instadose Canada. The OSC alleges that investor funds were diverted to the benefit of Mr. Sanders, his family, and associates. The OSC further alleges that Instadose Canada materially misrepresented the nature of the company’s business. Mr. Sanders retained legal counsel in Canada for the purpose of vigorously defending himself against the Charge. Mr. Sanders’ first scheduled court appearance on this matter occurred on Monday, August 16, 2021. It was determined at the First Appearance that the matter be adjourned until 2022. As of March 15, 2022, no new appearance has been scheduled.

Although Mr. Sander is not a 10% shareholder and resigned from all of his positions with the Company and Instadose Canada, he is still actively involved with some of the Company’s joint venture partners on an operational basis. An unfavorable outcome relating to the OSC changes may negatively affect the Company’s relationships with these joint venture partners in the future.

ITEM 2. UNREGISTERED SALES OF SECURITIES AND USE OF PROCEEDS

Not applicable.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

Not Applicable

ITEM 4. MINE SAFETY DISCLOSURE

None

Table of Contents

ITEM 5. OTHER INFORMATION

SEC Trading Suspension

On November 23, 2021, the Company was notified by the SEC that it had ordered, pursuant to Section 12(k) of the Securities Exchange Act of 1934, that trading in the securities of the above-listed Company is suspended for the period from 9:30 a.m. EDT on November 24, 2021, through 11:59 p.m. EDT on December 8, 2021.

The Order stated that it appears to the Securities and Exchange Commission that the public interest and the protection of investors require a suspension in the trading of the securities of the Company (CIK No. 0001697587), a Nevada corporation whose principal place of business is listed as Chesapeake, Virginia, because of questions and concerns regarding the adequacy and accuracy of information about Company in the marketplace, including:

	(1)	significant increases in the stock price and share volume unsupported by the company’s assets and financial information;
	(2)	trading that may be associated with individuals related to a control person of Instadose Pharma; and
	(3)	the operations of Instadose Pharma’s Canadian affiliate.

As of November 19, 2021, the common stock of Company was quoted and traded on OTC Pink whose parent company is OTC Markets Group Inc., under the symbol INSD, had seven market makers, and was eligible for the “piggyback” exception of Rule 15c2- 11(f)(3) of the Securities Exchange Act of 1934 (“Exchange Act”).

The Commission is of the opinion that the public interest and the protection of investors require a suspension of trading in the securities of the above-listed company.

As of the date of these financial statements, the Company has resumed trading on OTC markets, however, the symbol has been marked with a “CE” designation (Caveat Emptor).

Plan of Arrangement

On December 31, 2021, the Company closed on the Plan of Arrangement approved by the Supreme Court of British Columbia on October 19, 2021, by and between the Company and Instadose Pharma Corp., a British Columbia corporation (“Instadose Canada”). At Closing, the Company acquired all of the issued and outstanding common shares of Instadose Canada. Instadose Canada shareholders received 1.34 shares of the Company’s common stock in exchange for each share of Instadose Canada common stock for an aggregate of 456,930,654 shares of the Company’s common stock.

The transaction resulted in a change of control and a change in management.

South Africa Medicinal Cannabis Shipment

On January 5, 2022, Instadose announced its delivery of 2.125 metric tons of Medicinal Cannabis Flower (the “Product”) on December 25, 2021 from South Africa to North Macedonia which was sold and destined for Instadose’s licensed pharmaceutical clients (the “Clients”) in the European Union. Upon physical inspection and further due diligence as to the specifications required by the Clients, it was determined that the Product did not meet the standards to qualify as European Union medicinal cannabis product (“Compliant Cannabis”). Instadose is in the process of exploring all avenues to sell this Product, however, cannot ensure the eventual sale of the Product at this time. Instadose is currently in the process of determining the securement of Compliant Cannabis for future Instadose Sales.

Table of Contents

PART III

ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES

(a)(1) List of Financial statements included in Part II hereof

Balance Sheets, February 28, 2022, and May 31, 2021

Statements of Operations for the three and nine months ended February 28, 2022, and 2021

Statements of Stockholders’ Equity (Deficit) for the nine months ended February 28, 2022, and 2021

Statements of Cash Flows for the three and nine months ended February 28, 2022, and 2021

Notes to the Financial Statements

(a)(2) List of Financial Statement schedules included in Part IV hereof: None.

(a)(3) Exhibits

The following exhibits are included herewith:

Exhibit No.		Description
31		Certification of Chief Executive Officer and Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32		Certification of Chief Executive Officer and Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS*		XBRL Instance Document
101.SCH*		XBRL Taxonomy Extension Schema Document
101.CAL*		XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*		XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*		XBRL Taxonomy Extension Label Linkbase Document
101.PRE*		XBRL Taxonomy Extension Presentation Linkbase Document

____________

*XBRL (Extensible Business Reporting Language) information is furnished and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.

Table of Contents

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the ~~registrant~~Company has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	~~INSTADOSE PHARMA CORP.~~ ~~(formerly Mikrocoze Inc.)~~Instadose Pharma Corp. ~~(Registrant)~~

~~Date: October 13, 2021~~	~~By:~~	~~/s/ Terry Wilshire~~
		~~Terry Wilshire President and Director~~
Date: May 9, 2022	By:	~~Principal and~~ /s/ Alex Wylie
		Alex Wylie
		Chief Executive Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Company and in the capacities and on the dates indicated.

/s/ Alex Wylie	CEO, CFO, Controller	May 9, 2022
	~~Principal Financial Officer~~ ~~Principal Accounting Officer~~Director,

/s/ Ann Barnes	Director	May 9, 2022


/s/ Peter Wirth	Director	May 9, 2022

1847

	August 31, 2021			November 30, 2020
	(Unaudited)
ASSETS

CURRENT ASSETS
Cash	$	0		$	65

TOTAL ASSETS	$	0		$	65

LIABILITIES AND STOCKHOLDERS’ DEFICIT

CURRENT LIABILITIES
Accounts payable	$	24,259		$	338
Due to related party		88,974			82,085

TOTAL CURRENT LIABILITIES		113,233			82,423

COMMITMENTS AND CONTINGENCIES		0			0

STOCKHOLDERS’ DEFICIT
Preferred stock, par value $0.0001, 1,000,000 shares authorized, 0 issued and outstanding		0			0
Common stock, par value $0.0001, 700,000,000 shares authorized, 75,000,000 and 75,000,000 shares issued and outstanding, respectively		7,500			7,500
Additional paid-in capital		98,585			16,500
Accumulated deficit		(219,318	)		(106,358	)

TOTAL STOCKHOLDERS’ DEFICIT		(113,233	)		(82,358	)

TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	$	0		$	65

	Three months ended August 31, 2021			Three months ended August 31, 2020			Nine months ended August 31, 2021			Nine months ended August 31, 2020

REVENUE
Product sales	$	0		$	0		$	0		$	0
Cost of goods sold		0			0			0			0

GROSS PROFIT		0			0			0			0

OPERATING EXPENSES
General and administrative	$	2,704		$	583		$	14,275		$	3,289
Professional fees		50,125			3,560			98,685			14,460

TOTAL OPERATING EXPENSES		(52,829	)		(4,143	)		(112,960	)		(17,749	)

NET LOSS		(52,829	)		(4,143	)		(112,960	)		(17,749	)

NET LOSS PER COMMON SHARE – BASIC AND DILUTED	$	(0.00	)	$	(0.00	)	$	(0.00	)	$	(0.00	)

WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING – BASIC AND DILUTED		75,000,000			75,000,000			75,000,000			75,000,000

	Common Stock					Additional
	Number of shares			Amount		Paid-in Capital		Accumulated Deficit			Total

Balance, November 30, 2020		75,000,000		$	7,500	$	16,500	$	(106,358	)		(82,358	)

Loan forgiveness – related party		-	��		0		82,085					82,085

Net loss for the period ended February 28, 2021		-			0		0		(12,169	)		(12,169	)

Balance, February 28, 2021		75,000,000		$	7,500	$	98,585	$	(118,527	)	$	(12,442	)

Net loss for the period ended May 31, 2021		-			0		0		(47,962	)		(47,962	)

Balance, May 31, 2021		75,000,000		$	7,500	$	98,585	$	(166,489	)	$	(60,404	)

Net loss for the period ended August 31, 2021		-			0		0		(52,829	)		(52,829	)

Balance, August 31, 2021		75,000,000		$	7,500	$	98,585	$	(219,318	)	$	(113,233	)

	Nine-months ended August 31, 2021			Nine-months ended August 31, 2020

CASH FLOWS FROM OPERATING ACTIVITIES
Net loss for the period	$	(112,960	)	$	(17,749	)
Adjustments to reconcile net loss to net cash used in operating activities
Expenses paid on behalf of the Company by related party		88,974			12,046
Changes in operating assets and liabilities
Accounts payable		23,921			5,468

NET CASH USED IN OPERATING ACTIVITIES		(65	)		(235	)

CASH FLOWS FROM INVESTING ACTIVITIES		0			0

CASH FLOWS FROM FINANCING ACTIVITIES
Related party advances		0			330

NET CASH PROVIDED BY FINANCING ACTIVITIES		0			330

NET CHANGE IN CASH		(65	)		95

CASH, BEGINNING OF PERIOD		65			0

CASH, END OF PERIOD	$	0		$	95

SUPPLEMENTAL CASH FLOW INFORMATION AND NONCASH INVESTING AND FINANCING ACTIVITIES:

Cash paid during the period for:
Interest	$	0		$	0

Income taxes	$	0		$	0

Forgiveness of related party debt	$	82,085		$	0

Nine Months Ended

February 28, 2022

February 28, 2021